var title_f39_52_40768="Lateral pancreaticojej AGA";
var content_f39_52_40768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral pancreaticojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40768=[""].join("\n");
var outline_f39_52_40768=null;
var title_f39_52_40769="Probiotics in primary prevention of allergic disease";
var content_f39_52_40769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of studies using probiotics in primary prevention of allergic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"10\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Investigator(s)/publication date(s)/study location",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Study protocol",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Results",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Participants",
"       </td>",
"       <td class=\"subtitle2\">",
"        Type of probiotic(s) and dosage",
"       </td>",
"       <td class=\"subtitle2\">",
"        Prenatal duration",
"       </td>",
"       <td class=\"subtitle2\">",
"        Postnatal duration",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reduction in eczema",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reduction in sensitization",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reduction in other allergic disease",
"       </td>",
"       <td class=\"subtitle2\">",
"        Effect on colonization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Kalliom&auml;ki, et al.",
"        </p>",
"        <p>",
"         2001, 2003, 2007",
"        </p>",
"        <p>",
"         Turku, Finland",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 132 completed (of initial 159)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG (1 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Two to four weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (To breastfeeding mother, only directly to infant if not breastfeeding)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         At two, four, and seven years",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO*",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        * Trends of more rhinitis and asthma in the probiotic groups at four and seven years of age.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Rautava, et al.",
"        </p>",
"        <p>",
"         2006",
"        </p>",
"        <p>",
"         Turku, Finland",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any need for artificial feeding before two months of age",
"        </p>",
"        <p>",
"         n = 72 completed (of initial 81)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Lactobacillus rhamnosus",
"         </em>",
"         GG (1 x 10",
"         <sup>",
"          10",
"         </sup>",
"         CFU daily)",
"        </p>",
"        <p>",
"         and",
"        </p>",
"        <p>",
"         <em>",
"          Bifidobacterium lactis",
"         </em>",
"         Bb-12 (1 x 10",
"         <sup>",
"          10",
"         </sup>",
"         CFU daily)",
"        </p>",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        <p>",
"         Before 2 months until 12 months",
"        </p>",
"        <p>",
"         (In infant formula)",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        The study was designed to assess effect of probiotics on susceptibility to infections (not allergy prevention). Increased serum sCD14 and IgA in probiotic group.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <p>",
"         Kocourkov&aacute;, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         Prague, Czechia",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Three groups:",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        <em>",
"         E.coli serotype",
"        </em>",
"        O83:K24:H31 (8 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU given three times/week)",
"       </td>",
"       <td rowspan=\"3\">",
"        Not given",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         From day two until one month",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        YES",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        NO",
"       </td>",
"       <td rowspan=\"3\">",
"        NO",
"       </td>",
"       <td rowspan=\"3\">",
"        YES",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         &bull; Possible allergy preventing effect (mostly eczema) noted.",
"        </p>",
"        <p>",
"         &Delta; Reduced number of pathogenic organisms at three months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         - Allergic mother, colonized",
"        </p>",
"        <p>",
"         - Allergic mother, not colonized",
"        </p>",
"        <p>",
"         - Nonallergic mother",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        n = 144 completed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Taylor, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         Prescott, et al.",
"        </p>",
"        <p>",
"         2008",
"        </p>",
"        <p>",
"         Jensen, et al.",
"        </p>",
"        <p>",
"         2012",
"        </p>",
"        <p>",
"         Perth, Australia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mother with SPT+ allergic disease",
"        </p>",
"        <p>",
"         n = 189 completed (of initial 230)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus acidophilus",
"        </em>",
"        (LAVRI-A1) (3 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"        </p>",
"        <p>",
"         At one year",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        &loz; Sensitization more common in probiotic group at one year, but not at 2.5 or 5 years.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Kukkonen, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         Helsinki/Tampere, Finland",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         One or both parents with allergic disease",
"        </p>",
"        <p>",
"         n = 925 completed (of initial 1223)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG and LC705 (both 5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU twice daily); and",
"        <em>",
"         Bifidobacterium breve",
"        </em>",
"        Bb99 and",
"        <em>",
"         Proprionibacterium freudenreichii",
"        </em>",
"        ssp. shermanii JS (both 2 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU twice daily)",
"       </td>",
"       <td>",
"        Two to four weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         At two years",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        <p>",
"         &sect; Probiotic group also received prebiotic supplement (galacto-oligosaccharides).",
"        </p>",
"        <p>",
"         &yen; Trend for less IgE-associated allergic disease (p = 0.052).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Abrahamsson, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         Link&ouml;ping, Sweden",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 188 completed (of initial 232)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus reuteri",
"        </em>",
"        (1 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Two to four weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         12 months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         At two years",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        ������ Probiotic groups: less IgE-associated eczema in the second year, and less sensitization in subgroup with atopic mothers.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Kopp, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         Freiburg, Germany",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 94 completed (of initial 105)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG (1 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Four to six weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant for six months if not breastfeeding; to mother for three months and then to infant for three months if breastfeeding)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"        </p>",
"        <p>",
"         At two years",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        ������ Probiotic groups: increased rate of recurrent episodes of wheezing bronchitis.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Wickens, et al.",
"        </p>",
"        <p>",
"         2008, 2012",
"        </p>",
"        <p>",
"         Wellington and Auckland, New Zealand",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         One or both parents with allergic disease",
"        </p>",
"        <p>",
"         n = 474 (of initial 512)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Lactobacillus rhamnosus",
"         </em>",
"         HN001 (n = 157) (1 x 10",
"         <sup>",
"          10",
"         </sup>",
"         CFU daily)",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Bifidobacterium lactis",
"         </em>",
"         HN019 (1 x 10",
"         <sup>",
"          10",
"         </sup>",
"         CFU daily) (n = 158)",
"        </p>",
"       </td>",
"       <td>",
"        Two to five weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Two years",
"        </p>",
"        <p>",
"         (To infant regardless of feeding method)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         YES**",
"        </p>",
"        <p>",
"         At two and four years with",
"         <em>",
"          L. rhamnosus",
"         </em>",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         Reduced prevalence of rhinoconjunctivitis at four years with both",
"         <em>",
"          L. rhamnosus",
"         </em>",
"         and",
"         <em>",
"          B. lactis",
"         </em>",
"        </p>",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        ** Directly compared two probiotics; reduction in eczema at two and four years with",
"        <em>",
"         L. rhamnosus",
"        </em>",
"        and reduction in rhinoconjunctivitis at four years with both",
"        <em>",
"         L. rhamnosus",
"        </em>",
"        and",
"        <em>",
"         B. lactis",
"        </em>",
"        .",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Soh, et al.",
"        </p>",
"        <p>",
"         2009",
"        </p>",
"        <p>",
"         Singapore",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with SPT+ allergic disease",
"        </p>",
"        <p>",
"         n = 245 (of initial 253)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        (LPR) (1 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU daily) and",
"        <em>",
"         Bifidobacterium longum",
"        </em>",
"        (BL999) (6 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (In infant formula)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"        </p>",
"        <p>",
"         At one year",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Huurre, et al.",
"        </p>",
"        <p>",
"         2008",
"        </p>",
"        <p>",
"         Turku, Finland",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mother with current atopic disease",
"        </p>",
"        <p>",
"         n = 140 completed (of initial 171)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG and",
"        <em>",
"         Bifidobacterium lactis",
"        </em>",
"        (Bb-12) (1 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        From first trimester",
"       </td>",
"       <td>",
"        <p>",
"         Variable",
"        </p>",
"        <p>",
"         (To breastfeeding mother until end of exclusive breastfeeding)",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        &bull;&bull; Probiotics had no effect on infant sensitization at 12 months (except in subgroup with maternal sensitisation).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Kuitunen, Savilahti, et al.",
"        </p>",
"        <p>",
"         2009",
"        </p>",
"        <p>",
"         Helsinki, Finland",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Same study as Kukkonen, et al.",
"        </p>",
"        <p>",
"         2007",
"        </p>",
"        <p>",
"         n = 891 (of initial 1223)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG and LC705 (both 5 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU twice daily) and",
"        <em>",
"         Bifidobacterim breve",
"        </em>",
"        Bb99 and",
"        <em>",
"         Propionibacterium freudenreichii",
"        </em>",
"        ssp.",
"        <em>",
"         shermanii",
"        </em>",
"        JS (2 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU twice daily)",
"       </td>",
"       <td>",
"        Four weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"         <sup>",
"          &Delta;&Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Five year follow-up",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"         <sup>",
"          &Delta;&Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Five year follow-up",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"        </p>",
"        <p>",
"         Five year follow-up",
"        </p>",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        &Delta;&Delta; No overall allergy-preventive effect at five years. In subgroup of Caesarean-delivered children: probiotics associated with reduction in eczema and sensitization.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         West, et al.",
"        </p>",
"        <p>",
"         2009",
"        </p>",
"        <p>",
"         Ume&aring;, Sweden",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unselected population &asymp;2/3 in both groups with first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 171 completed (of initial 179)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus paracasei",
"        </em>",
"        ssp.",
"        <em>",
"         paracasei",
"        </em>",
"        F19 (1 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        <p>",
"         4 to 13 months, during weaning",
"        </p>",
"        <p>",
"         (In infant cereal)",
"        </p>",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        A significant difference in Th1/Th2 responses at 13 months (higher Th1/Th2 in probiotic group).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Niers, et al.",
"        </p>",
"        <p>",
"         2009",
"        </p>",
"        <p>",
"         Utrecht, Netherlands",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Allergic disease in either parent plus at least one sibling",
"        </p>",
"        <p>",
"         n = 98 completed (of initial 156)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactococcus lactis",
"        </em>",
"        W58,",
"        <em>",
"         Bifidobacterium lactis",
"        </em>",
"        W52, and",
"        <em>",
"         Bifidobacterium bifidum",
"        </em>",
"        W23 (1 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU each daily)",
"       </td>",
"       <td>",
"        Six weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         12 months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        <p>",
"         NO",
"        </p>",
"        <p>",
"         (Trend for",
"         <em>",
"          more",
"         </em>",
"         sensitization with probiotics)",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Kim, et al.",
"        </p>",
"        <p>",
"         2010",
"        </p>",
"        <p>",
"         Seoul",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 68 completed (of initial 112)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Bifidobacterium bifidum",
"        </em>",
"        BGN4,",
"        <em>",
"         Bifidobacterium lactis",
"        </em>",
"        AD011, and",
"        <em>",
"         Lactobacillus acidophilus",
"        </em>",
"        AD031 (1.6 x 10",
"        <sup>",
"         9",
"        </sup>",
"        CFU of each daily)",
"       </td>",
"       <td>",
"        Four to eight weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Three months to breastfeeding mother and then direct to infant for three months)",
"        </p>",
"       </td>",
"       <td>",
"        YES",
"        <sup>",
"         &loz;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        &loz;&loz; Reduced cumulative incidence and prevalence of eczema at 12 months.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Dotterud, et al.",
"        </p>",
"        <p>",
"         2010",
"        </p>",
"        <p>",
"         Trondheim, Norway",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unselected population &asymp;2/3 in both groups with first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 278 (of initial 415)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG,",
"        <em>",
"         Lactobacillus acidophilus",
"        </em>",
"        LA5, and",
"        <em>",
"         Bifidobacterium lactis",
"        </em>",
"        Bb-12 (5 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU of each daily)",
"       </td>",
"       <td>",
"        From 36 weeks gestation",
"       </td>",
"       <td>",
"        <p>",
"         Three months",
"        </p>",
"        <p>",
"         (To breastfeeding mother)",
"        </p>",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        Reduced eczema in first two years compared with placebo group, the effect most obvious in children without a family history of atopy.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Boyle, et al.",
"        </p>",
"        <p>",
"         2011",
"        </p>",
"        <p>",
"         Melbourne, Australia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 212 (of initial 250)",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG (1.8 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        From 36 weeks gestation",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        YES",
"       </td>",
"       <td>",
"        No effect on eczema at 12 months, two year follow-up still in progress.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Ou, et al.",
"        </p>",
"        <p>",
"         2012",
"        </p>",
"        <p>",
"         Kaohsiung, Taiwan",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mother with atopic disease and IgE &gt;100 kU/L and/or positive specific IgE",
"        </p>",
"        <p>",
"         n = 128 completed (of initial 191)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Lactobacillus rhamnosus",
"         </em>",
"         GG",
"        </p>",
"        <p>",
"         (1 x 10",
"         <sup>",
"          10",
"         </sup>",
"         CFU daily)",
"        </p>",
"       </td>",
"       <td>",
"        From second trimester",
"       </td>",
"       <td>",
"        For six months to mother if breastfeeding and direct to infant if not breastfeeding",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        Symptom scores of maternal allergic disease reduced in probiotic group. Mothers with IgE &gt;100 kU/L improved most and improvement was associated with higher IL-12 p70 levels.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Thornton, Morgan, et al.",
"        </p>",
"        <p>",
"         Swansea, UK",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Any first degree relative with allergic disease",
"        </p>",
"        <p>",
"         n = 600 intended",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus salivaris",
"        </em>",
"        (6.25 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily) and",
"        <em>",
"         Lactobacillus paracasei",
"        </em>",
"        and",
"        <em>",
"         Bifidobacterium infantis",
"        </em>",
"        and",
"        <em>",
"         Bifidobacterium bifidum",
"        </em>",
"        (each at 1.25 x 10",
"        <sup>",
"         8",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Two to four weeks before delivery",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant regardless of feeding method)",
"        </p>",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Cabana, et al.",
"        </p>",
"        <p>",
"         San Francisco, US",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Either parent with asthma",
"        </p>",
"        <p>",
"         n = 276 intended",
"        </p>",
"       </td>",
"       <td>",
"        <em>",
"         Lactobacillus rhamnosus",
"        </em>",
"        GG (1 x 10",
"        <sup>",
"         10",
"        </sup>",
"        CFU daily)",
"       </td>",
"       <td>",
"        Not given",
"       </td>",
"       <td>",
"        <p>",
"         Six months",
"        </p>",
"        <p>",
"         (Direct to infant)",
"        </p>",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        Pending",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Rautava, Isolauri, et al.",
"        </p>",
"        <p>",
"         2012",
"        </p>",
"       </td>",
"       <td>",
"        Mother with SPT+ allergic disease",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          L. rhamnosus",
"         </em>",
"         LPR and",
"         <em>",
"          B. longum",
"         </em>",
"         BL999",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          L. paracasei",
"         </em>",
"         and",
"         <em>",
"          B. longum",
"         </em>",
"         BL9",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Placebo",
"        </p>",
"        <p>",
"         Daily dose of each probiotic was 1 x 10",
"         <sup>",
"          9",
"         </sup>",
"         CFU",
"        </p>",
"       </td>",
"       <td>",
"        Two months before delivery",
"       </td>",
"       <td>",
"        Two months during breastfeeding to mother only",
"       </td>",
"       <td>",
"        <p>",
"         YES",
"        </p>",
"        <p>",
"         At two years and in both probiotic groups",
"        </p>",
"       </td>",
"       <td>",
"        NO",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        All mothers received vitamin and mineral supplementation in combination with probiotics or placebo.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows a list of the published and ongoing randomized controlled trials, which have used probiotics for the primary prevention of allergic disease.",
"    <br/>",
"    <strong>",
"     Search strategy for published studies:",
"    </strong>",
"    We included the following keywords: [probiotic OR Lactobacillus OR Bifidobacterium OR prebiotic OR synbiotic] AND [allergy OR allergic disease OR atopic dermatitis OR eczema]. We then selected all randomized controlled trials using the intervention of interest in humans and assessed allergic outcomes.",
"    <div class=\"footnotes\">",
"     n: number; CFU: colony forming unit; s: soluble; CD: cluster of differentiation; SPT: skin prick testing; SCORAD: scoring atopic dermatitis; Th1/2: T helper cells 1/2.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Johannsen H, Prescott SL. Practical prebiotics, probiotics and synbiotics for allergist: how useful are they? Clin Exp Allergy 2009; 39:1801. Copyright &copy; 2009 John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40769=[""].join("\n");
var outline_f39_52_40769=null;
var title_f39_52_40770="WHO weight for age boys 0 to 24 months";
var content_f39_52_40770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, boys 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40770=[""].join("\n");
var outline_f39_52_40770=null;
var title_f39_52_40771="The Allen test";
var content_f39_52_40771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    The Allen test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Allen test, the patient is instructed to make a fist, which will empty the blood from the hand and fingers (A). The examiner's thumbs are then pressed down across the thenar and hypothenar eminences to the wrist to occlude the radial and ulnar arteries. The patient then opens the hand, making sure not to overextend the fingers. The pressure on the ulnar artery is then released while the radial artery is still compressed (B). The hand does not fill with blood. Note the paleness of the hand on the right compared with the hand on left, indicating occlusion of the ulnar artery distal to the wrist (abnormal test result). If there is prompt return of color to the hand (indicating a normal test result), the test is repeated except this time pressure on the radial artery is released while the ulnar artery remains compressed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Olin JW, Lie JT, Thromboagiitis (Buerger's disease). In: Current management of hypertensive and vascular disease, Cookie JP, Frohlich ED, (Eds), Mosby-Year Book, St Louis 1992. p.265. Copyright &copy; Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40771=[""].join("\n");
var outline_f39_52_40771=null;
var title_f39_52_40772="Naphazoline (nasal): Patient drug information";
var content_f39_52_40772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Naphazoline (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/53/29523?source=see_link\">",
"     see \"Naphazoline (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/57/10131?source=see_link\">",
"     see \"Naphazoline (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9348230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Privine&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naphazoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other subst",
"1ff8",
"ances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705461",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sit in chair or lie down.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are in a chair, hold head back. If lying in bed, place a pillow under your shoulders and drop head back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put nose dropper into nose",
"1ff8",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       inch and drop in.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stay in same position for 2 minutes. This keeps this drug in your nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close 1 nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head forward a little.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put nose spray tube into other nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       While breathing in, press down once to release spray.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out from your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12264 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   1210",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-218.28.111.102-3C51B1EE61-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40772=[""].join("\n");
var outline_f39_52_40772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9348230\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024404\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024406\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024405\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024410\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024411\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024413\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024408\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024409\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024414\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024415\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/53/29523?source=related_link\">",
"      Naphazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/57/10131?source=related_link\">",
"      Naphazoline (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/60/15300?source=related_link\">",
"      Naphazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/47/19188?source=related_link\">",
"      Naphazoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/60/27587?source=related_link\">",
"      Naphazoline (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40773="Nitroprusside: Pediatric drug information";
var content_f39_52_40773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitroprusside: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"    see \"Nitroprusside: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/36/34371?source=see_link\">",
"    see \"Nitroprusside: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nitropress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nipride&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: Initial: 0.2 mcg/kg/minute and titrate to effect; doses up to  8 mcg/kg/minute have been reported; however, doses &ge;1.8 mcg/kg/minute are associated with increased cyanide concentration in pediatric patients, including neonates (Moffett, 2008); reported duration of therapy was typically &lt;6-7 days. Use in neonates has been described in several retrospective reports and case series; most recent and majority of patient experience is during cardiac surgery requiring cardiopulmonary bypass and postoperatively for afterload reduction (Benitz, 1985; Cachat, 2004; Furck, 2010; Kiran, 2006; Motta, 1995; Williams, 1994);  use for 6 days at a maximum dose of 2.5 mcg/kg/minute produced profound lactic acidosis in one neonate (Meyer, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"      see \"Nitroprusside: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children : Continuous I.V. infusion: Start 0.3-0.5 mcg/kg/minute, titrate to effect; doses &ge;1.8 mcg/kg/minute are associated with increased cyanide concentration in pediatric patients (Moffett, 2008); rarely need &gt;4 mcg/kg/minute; maximum dose: 8-10 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Continuous I.V. infusion: Initial: 0.3-0.5 mcg/kg/minute; increase in increments of 0.5 mcg/kg/minute, titrating to the desired hemodynamic effect or the appearance of headache or nausea; usual dose: 3 mcg/kg/minute; rarely need &gt;4 mcg/kg/minute; maximum: 10 mcg/kg/minute. When &gt;500 mcg/kg is administered by prolonged infusion of faster than 2 mcg/kg/minute, cyanide is generated faster than an unaided patient can handle.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitropress&reg;: 25 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. continuous infusion only via controlled infusion device. Not for direct injection; must dilute prior to administration; dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W (preferred). Solution should be protected from light, but not necessary to wrap administration set or I.V. tubing. Final concentration for administration: Usual maximum: 200 mcg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W; in fluid restricted patients a final maximum concentration of 1000 mcg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W has been used. May also dilute in LR or NS to 50 or 100 mcg/mL. Do not add other medications to nitroprusside solutions.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     200",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W (preferred), LR, NS;",
"     <b>",
"      Note:",
"     </b>",
"     Exposure to light causes decompensation regardless of the diluent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil, argatroban, atracurium, bivalirudin, caffeine citrate, calcium chloride, calcium gluconate, dexmedetomidine, diltiazem, dobutamine, dobutamine with dopamine, dobutamine with lidocaine, dobutamine with nitroglycerin, dopamine, dopamine with lidocaine, dopamine with nitroglycerin, enalaprilat, epinephrine, esmolol, famotidine, furosemide, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;),  inamrinone, indomethacin, insulin (regular), isoproterenol, labetalol, lidocaine, lidocaine with nitroglycerin, magnesium sulfate, micafungin, midazolam, milrinone, morphine, nesiritide, norepinephrine, nitroglycerin, pancuronium, potassium chloride, potassium phosphate, procainamide, propofol, tacrolimus, theophylline, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Drotrecogin alfa, levofloxacin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, cisatracurium, haloperidol, metoprolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discard solution 24 hours after reconstitution and dilution; discard highly colored solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertensive crises; CHF; used for controlled hypotension during anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nitroprusside may be confused with nitroglycerin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F202235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, ECG changes, flushing, hypotension (excessive), palpitation, substernal distress, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, dizziness, headache, intracranial pressure increased, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis (secondary to cyanide toxicity), hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, ileus, nausea, retching, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia, platelet aggregation decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperreflexia (secondary to thiocyanate toxicity), muscle twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis (secondary to thiocyanate toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus (secondary to thiocyanate toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hyperoxemia (secondary to cyanide toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cyanide toxicity, diaphoresis, thiocyanate toxicity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitroprusside or any component of the formulation; treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); high output failure; congenital optic atrophy or tobacco amblyopia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe renal impairment, hepatic failure, hypothyroidism, hyponatremia, increased intracranial pressure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only as an infusion with D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; continuously monitor patient's blood pressure",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may cause precipitous decreases in blood pressure. Except when used briefly or at low (&lt;2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cyanide or thiocyanate toxicity may occur; risk increased  in patients with decreased renal or liver function or when using excessive doses. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled, then discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13263869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels.  However, information related to use in pregnancy is limited.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; monitor for cyanide and thiocyanate toxicity; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (&gt;3 days) or dose &ge;4 mcg/kg/minute or patient has renal dysfunction; monitor cyanide blood levels in patients with decreased hepatic function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Thiocyanate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: 35-100 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fatal: &gt;200 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cyanide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal &lt;0.2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal (smoker): &lt;0.4 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxic: &gt;2 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Potentially lethal: &gt;3 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotensive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 1-10 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to cyanide by erythrocyte and tissue sulfhydryl group interactions; cyanide is converted in the liver by the enzyme rhodanase to thiocyanate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: &lt;10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thiocyanate: 2.7-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Thiocyanate is excreted in the urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thiocyanate toxicity includes psychoses, blurred vision, confusion, weakness, tinnitus, seizures; cyanide toxicity includes metabolic acidosis, tachycardia, pink skin, decreased pulse, decreased reflexes, altered consciousness, coma, almond smell on breath, methemoglobinemia, dilated pupils",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Benitz WE, Malachowski N, Cohen RS, et al, \"Use of Sodium Nitroprusside in Neonates: Efficacy and Safety,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 106(1):102-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/3917495/pubmed\" id=\"3917495\" target=\"_blank\">",
"        3917495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cachat F, Bogaru A, Micheli JL, et al, \"Severe Hypertension and Massive Proteinuria in a Newborn With Renal Artery Stenosis,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2004, 19(5):544-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/14986083/pubmed\" id=\"14986083\" target=\"_blank\">",
"        14986083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cachat F and Guignard JP, \"Reply to the Letter From C. von Schnakenburg and M. Kr&uuml;ger,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2004, 19:1308-09.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furck AK, Hansen JH, Uebing A, et al, \"The Impact of Afterload Reduction on the Early Postoperative Course After the Norwood Operation - A 12-year Single-Centre Experience,\"",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 2010, 37(2):289-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/19800251/pubmed\" id=\"19800251\" target=\"_blank\">",
"        19800251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kiran U, Zuber K, and Kakani M, \"Combination of Low-Dose Phenoxybenzamine and Sodium Nitroprusside in Children Undergoing Cardiac Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2006, 20(2):291-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/16616682/pubmed\" id=\"16616682\" target=\"_blank\">",
"        16616682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meyer S, Baghai A, Sailer NL, et al, \"Lactic Acidosis Caused by Sodium Nitroprusside in a Newborn With Congenital Heart Disease,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2005, 164(4):253-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/15666157/pubmed\" id=\"15666157\" target=\"_blank\">",
"        15666157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moffett BS and Price JF, \"Evaluation of Sodium Nitroprusside Toxicity in Pediatric Cardiac Surgical Patients,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(11):1600-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/18957627/pubmed\" id=\"18957627\" target=\"_blank\">",
"        18957627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motta P, Mossad E, Toscana D, et al, \"Comparison of Phenoxybenzamine to Sodium Nitroprusside in Infants Undergoing Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2005, 19(1):54-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/15747270/pubmed\" id=\"15747270\" target=\"_blank\">",
"        15747270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Schnakenburg C and Kr&uuml;ger M, \"Note of Caution for the Use of Sodium Nitroprusside in Neonatal Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2004, 19(11):1307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/52/40773/abstract-text/15338387/pubmed\" id=\"15338387\" target=\"_blank\">",
"        15338387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams RS, Mickell JJ, Young ES, et al, \"Methemoglobin Levels During Prolonged Combined Nitroglycerin and Sodium Nitroprusside Infusions in Infants After Cardiac Surgery,\"",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 1994, 8(6):658-62.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12648 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40773=[""].join("\n");
var outline_f39_52_40773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709173\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817125\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054446\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675229\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054441\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202177\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202162\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054451\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473002\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202236\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054443\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054450\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202238\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202235\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054455\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054440\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054439\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299769\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202171\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202173\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13263869\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054445\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054449\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054438\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054453\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054454\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054456\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12648|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=related_link\">",
"      Nitroprusside: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/36/34371?source=related_link\">",
"      Nitroprusside: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40774="Supravalvar aortic stenosis";
var content_f39_52_40774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supravalvar aortic stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     David W Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     John F Keane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40774/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/52/40774/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular outflow tract (LVOT) obstructive lesions account for approximately 6 percent of cases of congenital heart disease in children; in one series, the incidence was estimated to be 6 in 10,000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Obstruction can occur at valvar (by far the most common), subvalvar, and supravalvar levels.",
"   </p>",
"   <p>",
"    Supravalvar aortic stenosis will be reviewed here. Valvar and subvalvar aortic stenosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=see_link\">",
"     \"Subvalvar aortic stenosis (subaortic stenosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPRAVALVAR AORTIC STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvar AS is the least common form of left ventricular (LV) outflow tract obstruction. Among children with congenital AS, supravalvar AS has accounted for 8 to 14 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least two anatomic forms of supravalvar AS. The majority of patients (60 to 75 percent) have an hourglass deformity, consisting of a discrete constriction of a thickened ascending aorta at the superior aspect of the sinuses of Valsalva (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"mobipreview.htm?15/62/16355\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. More diffuse narrowing for a variable distance along the ascending aorta is seen in 25 to 40 percent. There are also rare reports of a discrete membranous stenosis, which may be a variant of the hourglass deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major histologic features of the ascending aorta in supravalvar AS are a thickened and dysplastic media with an increased number of hypertrophied smooth muscle cells, increased collagen content, and a paucity of elastic tissue with disorganized elastin fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Further support for an abnormality in elastin is the high frequency of supravalvar AS in patients with Williams syndrome, which is due to a mutation in the elastin gene. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology'",
"    </a>",
"    below.) Supravalvar AS in these patients has been characterized as one manifestation of an elastin arteriopathy.",
"   </p>",
"   <p>",
"    Supravalvar AS is associated with several other cardiovascular anomalies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aortic valve leaflets may be thickened, redundant, and have reduced mobility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. In one report, the aortic valve leaflets were partially adherent to the stenosing supravalvar ridge in more than one-half of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronary artery stenosis can occur due to focal or diffuse coronary narrowing or due to obstruction by redundant, dysplastic aortic valve leaflets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9,11\">",
"       9,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coarctation of the aorta and ostial stenoses of the carotid, renal, iliac, and other peripheral arteries are seen in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary artery stenoses, either of the main pulmonary artery or of branch pulmonary arteries, are common, occurring in about one-half of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In contrast to the systemic arterial stenoses described above, pulmonary artery stenoses typically decrease in severity over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mitral valve is usually normal.",
"   </p>",
"   <p>",
"    In our experience at the Children's Hospital Boston (1988-2002), supravalvar aortic stenosis (134 patients) was associated with aortic regurgitation in 41 percent; with sub-valvar aortic stenosis in 10 percent, and only one patient had a bicommissural aortic valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiology of supravalvar AS is similar to valvar and subvalvar stenosis. Significant obstruction is associated with a hyperdynamic, hypertrophied left ventricle. Elevated systolic pressure in the aortic root may be responsible for the associated coronary artery enlargement and dilatation of the sinuses of Valsalva that are often seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9\">",
"     9",
"    </a>",
"    ]. As noted above, coronary artery stenosis can occur, and subendocardial ischemic changes may be seen even without coronary narrowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supravalvar AS creates a systolic jet that tends to hug the aortic wall and transfer kinetic energy into the right innominate artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/6\">",
"     6",
"    </a>",
"    ]. This phenomenon, known as the Coanda effect, is the mechanism that explains higher blood pressure in the right than left arm in most patients with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvar AS occurs in four settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a feature of Williams syndrome, which is also characterized by unusual facial features, intellectual disability (mental retardation), and hypercalcemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/12,18,19\">",
"       12,18,19",
"      </a>",
"      ]. In a report from a multicenter consortium for children with Williams syndrome and cardiovascular lesions who underwent cardiac catheterization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      operation, supravalvar AS was diagnosed in 169 of 242 patients, followed by pulmonary stenosis in 130 patients and coarctation or aortic arch hypoplasia in 32 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/19\">",
"       19",
"      </a>",
"      ]. Ninety-two patients had more than one finding, including 80 with both supravalvar AS and pulmonary stenosis.",
"     </li>",
"     <li>",
"      A familial form without features of Williams syndrome. It is inherited in an autosomal dominant pattern [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/18,20,21\">",
"       18,20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In sporadic patients without a family history [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with homozygous familial hypercholesterolemia (FH), a rare autosomal dominant disorder in which supravalvar AS occurs in as many as 44 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. Supravalvar AS also is seen less frequently in heterozygotes (4 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/24\">",
"       24",
"      </a>",
"      ]. This disorder typically affects adults and rarely is seen in children. It is not clear whether the lesion is solely a manifestation of aortic atherosclerosis or whether an underlying structural abnormality is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a 1983 series of 25 patients with supravalvar AS age 1 to 49 years, the distribution of Williams syndrome, the familial form, and the sporadic form was 28, 20, and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4\">",
"     4",
"    </a>",
"    ]. It is not apparent whether the authors looked for FH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic studies have also demonstrated that the non-FH forms of supravalvar AS are caused either by mutations in, or in Williams syndrome, deletion of the elastin gene located on chromosome 7q11.23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/18,25-29\">",
"     18,25-29",
"    </a>",
"    ]. The deletion in Williams syndrome includes genes other than the elastin gene that are responsible for the other manifestations of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. As an example, loss of one allele of the LIM-kinase gene is thought to be responsible for the defects in visuospatial cognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The gene deletions responsible for other manifestations of this syndrome are not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Williams syndrome is associated with a number of abnormalities in addition to supravalvar AS and defects in visuospatial cognition. These include mental retardation, hypercalcemia, renovascular hypertension, facial abnormalities, and short stature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=see_link\">",
"     \"Williams-Beuren syndrome\"",
"    </a>",
"    .) In contrast, supravalvar AS is usually the only abnormality in patients with familial or sporadic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4,18,20\">",
"     4,18,20",
"    </a>",
"    ], although peripheral pulmonary stenosis has been described in at least one family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations related to the supravalvar disease include those due to the left ventricular outflow obstruction and possible coronary ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. The following reports illustrate the range of cardiac symptoms that have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 44 patients with Williams syndrome and a structural heart defect, 35 (80 percent) had symptoms at birth, including 34 with failure to thrive, four with heart failure, two with cyanosis, and one with absent femoral pulses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two reports including 174 patients (5 days to 27 years of age) undergoing surgical correction of supravalvar AS not due to Williams syndrome, the NYHA (New York Heart Association) functional class prior to surgery was I in 11 percent, II in 57 percent, III in 26 percent, and IV in 6 percent (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvar AS often is detected by the findings on cardiac auscultation (",
"    <a class=\"graphic graphic_table graphicRef51024 \" href=\"mobipreview.htm?42/11/43196\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/17\">",
"     17",
"    </a>",
"    ]. Affected patients typically have a loud systolic ejection murmur best heard at the first right intercostal space; there is no associated ejection click or diastolic murmur of aortic regurgitation, findings that are common in valvar AS. In the series of 44 patients described above, 28 had a murmur detected during the newborn period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aortic component of the second heart sound may be accentuated due to elevated pressure in the aorta proximal to the stenosis. A thrill at the first right intercostal space is common.",
"   </p>",
"   <p>",
"    Other common findings are suprasternal notch thrills, unequal carotid pulsations due to ostial stenosis, and a higher blood pressure in the right compared to the left arm due to the high pressure jet in the ascending aorta (the Coanda effect) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. A blood pressure difference between the two arms of more than 10 mmHg has been noted in approximately two-thirds of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of supravalvar AS is confirmed by echocardiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"mobipreview.htm?15/62/16355\">",
"     image 1",
"    </a>",
"    ). Echocardiography also can assess LV function and hypertrophy and estimate the gradient across the obstruction. In practice, an accurate Doppler measurement of the aortic gradient frequently is sufficient to determine which patients are candidates for surgical correction of isolated lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/37\">",
"     37",
"    </a>",
"    ]. Magnetic resonance imaging with angiography also provides excellent anatomic detail of supravalvar aortic obstruction, together with associated aortic branch vessel disease, if present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/38\">",
"     38",
"    </a>",
"    ]. MRI is used when acoustic windows are poor, or when physical examination or other findings suggest associated lesions of the vascular tree (eg, branch vessel involvement).",
"   </p>",
"   <p>",
"    The chest radiograph typically is normal, although some patients have mild to moderate cardiomegaly. The ECG shows left ventricular hypertrophy in many older patients, which may be accompanied by a strain pattern. In addition, the ECG may show right ventricular hypertrophy in patients with significant pulmonary artery obstruction due to peripheral pulmonary artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac catheterization provides precise hemodynamic and angiographic evaluation, but is not routinely necessary (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"mobipreview.htm?15/62/16355\">",
"     image 1",
"    </a>",
"    ). It may be performed when additional lesions are suspected, such as coronary, carotid, renal, or pulmonary artery stenoses. Pulmonary artery stenoses often are amenable to balloon dilation. When bilateral outflow obstruction is present and significant, catheterization may be extremely hazardous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy for supravalvar AS, whether discrete or diffuse, consists of surgical correction of the obstruction. Stent placement has been reported in a few patients, with mixed results.",
"   </p>",
"   <p>",
"    Surgery in supravalvar AS usually is performed at gradient levels that are lower than in valvar AS to avoid the progressive obstruction that occurs in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/5,39\">",
"     5,39",
"    </a>",
"    ]. The likelihood of progression varies with the initial gradient. This was illustrated in a study of 45 patients with supravalvar AS diagnosed in infancy and followed for 13 years: 32 patients with a pressure gradient less than 20 mmHg had no evidence of progression during the first two decades of life, while 13 patients with a gradient exceeding 20 mmHg had progression of the mean gradient from 35 to 53 mmHg, with eight requiring surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for surgery are uncertain because experience is limited. Since surgery is usually curative for the discrete form (in contrast to valvar AS), we recommend operation for symptomatic disease and for patients with a measured gradient at catheterization of more than 30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flap plasty techniques usually are successful in alleviating the discrete type of stenosis which, as noted above, accounts for 60 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/36,39,41\">",
"     36,39,41",
"    </a>",
"    ]. Techniques include simple single patch enlargement into the sinotubular junction just above the aortic root, bifurcated patches extended into two sinuses, and separate three sinus patch enlargement methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/41\">",
"     41",
"    </a>",
"    ]. In one report of 75 patients, the mortality rate was less, need for reoperation was reduced, and hemodynamics were improved by multiple sinus reconstructions compared to single sinus patch enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relief of diffuse obstruction is more complex; surgical options include extensive endarterectomy with patch aortoplasty or resection of the stenotic segment with end-to-end anastomosis to the distal ascending aorta, with or without insertion of a pulmonary autograft (the Ross procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/10,36\">",
"     10,36",
"    </a>",
"    ]. Transcatheter stent placement is an effective alternative or adjunctive therapy in some patients, particularly those with involvement of smaller aortic branch vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after surgical correction of supravalvar AS depend upon the nature of the stenosis and the presence of associated lesions. A few studies with long-term follow-up have been reported. The results generally have been similar, with variability due to different patient populations, indications for surgery, and perhaps surgical technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/36,39,42\">",
"     36,39,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operative mortality ranged from 1 to 9 percent.",
"     </li>",
"     <li>",
"      Among patients discharged from the hospital, survival ranged from 94 to 98 percent at 10 years and 77 to 97 percent at 20 years. The incidence of reoperation ranged from 14 to 19 percent.",
"     </li>",
"     <li>",
"      In different trials, the main predictors of worse survival and more frequent reoperation were the presence of diffuse as opposed to discrete stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/39\">",
"       39",
"      </a>",
"      ] and the presence of associated aortic valve disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40774/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In our experience, operative risk is relatively higher in patients with diffuse arteriopathy and biventricular outflow obstruction. These typically are patients with Williams syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2007 American Heart Association guidelines, antibiotic prophylaxis to prevent bacterial endocarditis is no longer recommended in patients with supravalvar AS except in those with a prior history of endocarditis or with a repair that required prosthetic material or device. In the latter, antibiotic prophylaxis is recommended for the first six months after repair unless a residual defect is present, in which cause prophylactic antibiotics are continued beyond the six month period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H965149\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supravalvar is the least common form of left ventricular outflow tract (LVOT) obstruction, accounting for 8 to 14 percent of all cases of aortic stenosis (AS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 60 to 75 percent of patients with supravalvar AS, there is a discrete constriction of a thickened ascending aorta at the superior aspect of the sinuses of Valsalva (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"mobipreview.htm?15/62/16355\">",
"       image 1",
"      </a>",
"      ), and in the remaining cases, there is a more diffuse narrowing along the ascending aorta. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supravalvar AS is often associated with other cardiovascular anomalies including coronary artery stenosis, coarctation of the aorta, aortic regurgitation, and pulmonary artery stenosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supravalvar AS is one of the characteristic findings of Williams syndrome along with unusual elfin facies, intellectual disability, and hypercalcemia. Williams syndrome is caused by a deletion of the elastin gene on chromosome 7q11.23. Other forms of supravalvar AS are also associated with mutations of the elastin gene. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with significant supravalvar AS, there is a hyperdynamic, hypertrophied left ventricle. The progression of obstruction varies and appears to depend on the initial gradient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings of supravalvar AS depend on the degree of LVOT obstruction and the presence of other cardiac abnormalities, especially coronary artery stenosis. The range of cardiac findings varies from no or few symptoms to heart failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main physical finding of supravalvar AS is a loud systolic ejection murmur heard best at the first right intercoastal space. It is not accompanied by a click or diastolic murmur, which are common physical findings of valvar AS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of supravalvar AS is confirmed by echocardiography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56928 \" href=\"mobipreview.htm?15/62/16355\">",
"       image 1",
"      </a>",
"      ). Echocardiography also can assess LV function and hypertrophy, and estimate the pressure gradient across the obstruction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive treatment supravalvar AS is surgical correction. Indications for surgery are uncertain because of limited outcome data. At our center, we suggest surgical correction for patients with a gradient greater than 30 mmHg measured by cardiac catheterization. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgical repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocarditis prophylaxis is no longer recommended in patients with supravalvar AS except for those with a previous history of endocarditis, or with a repair with prosthetic material or device. In these latter patients, prophylactic antibiotics are given only after the first six months after repair unless a residual defect is present. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endocarditis prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outcome varies following surgical repair and is dependent on the nature of the stenosis and presence of associated lesions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/1\">",
"      Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/2\">",
"      Kitchiner D, Jackson M, Malaiya N, et al. Incidence and prognosis of obstruction of the left ventricular outflow tract in Liverpool (1960-91): a study of 313 patients. Br Heart J 1994; 71:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/3\">",
"      Liu CW, Hwang B, Lee BC, et al. Aortic stenosis in children: 19-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 59:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/4\">",
"      Flaker G, Teske D, Kilman J, et al. Supravalvular aortic stenosis. A 20-year clinical perspective and experience with patch aortoplasty. Am J Cardiol 1983; 51:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/5\">",
"      Keane JF, Fellows KE, LaFarge CG, et al. The surgical management of discrete and diffuse supravalvar aortic stenosis. Circulation 1976; 54:112.",
"     </a>",
"    </li>",
"    <li>",
"     Latson LA. Aortic stenosis: valvar, supravalvar, and fibromuscular subvalvar. In: The Science and Practice of Pediatric Cardiology, Garson A, Bricker JT, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/7\">",
"      Stamm C, Friehs I, Ho SY, et al. Congenital supravalvar aortic stenosis: a simple lesion? Eur J Cardiothorac Surg 2001; 19:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/8\">",
"      Vaideeswar P, Shankar V, Deshpande JR, et al. Pathology of the diffuse variant of supravalvar aortic stenosis. Cardiovasc Pathol 2001; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/9\">",
"      Stamm C, Li J, Ho SY, et al. The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. J Thorac Cardiovasc Surg 1997; 114:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/10\">",
"      McElhinney DB, Petrossian E, Tworetzky W, et al. Issues and outcomes in the management of supravalvar aortic stenosis. Ann Thorac Surg 2000; 69:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/11\">",
"      Thistlethwaite PA, Madani MM, Kriett JM, et al. Surgical management of congenital obstruction of the left main coronary artery with supravalvular aortic stenosis. J Thorac Cardiovasc Surg 2000; 120:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/12\">",
"      Eronen M, Peippo M, Hiippala A, et al. Cardiovascular manifestations in 75 patients with Williams syndrome. J Med Genet 2002; 39:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/13\">",
"      Wren C, Oslizlok P, Bull C. Natural history of supravalvular aortic stenosis and pulmonary artery stenosis. J Am Coll Cardiol 1990; 15:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/14\">",
"      Giddins NG, Finley JP, Nanton MA, Roy DL. The natural course of supravalvar aortic stenosis and peripheral pulmonary artery stenosis in Williams's syndrome. Br Heart J 1989; 62:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/15\">",
"      Vincent WR, Buckberg GD, Hoffman JI. Left ventricular subendocardial ischemia in severe valvar and supravalvar aortic stenosis. A common mechanism. Circulation 1974; 49:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/16\">",
"      van Son JA, Edwards WD, Danielson GK. Pathology of coronary arteries, myocardium, and great arteries in supravalvular aortic stenosis. Report of five cases with implications for surgical treatment. J Thorac Cardiovasc Surg 1994; 108:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/17\">",
"      French JW, Guntheroth WG. An explanation of asymmetric upper extremity blood pressures in supravalvular aortic stenosis: the Coanda effect. Circulation 1970; 42:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/18\">",
"      Morris CA. Genetic aspects of supravalvular aortic stenosis. Curr Opin Cardiol 1998; 13:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/19\">",
"      Pham PP, Moller JH, Hills C, et al. Cardiac catheterization and operative outcomes from a multicenter consortium for children with williams syndrome. Pediatr Cardiol 2009; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/20\">",
"      Schmidt MA, Ensing GJ, Michels VV, et al. Autosomal dominant supravalvular aortic stenosis: large three-generation family. Am J Med Genet 1989; 32:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/21\">",
"      Kumar A, Stalker HJ, Williams CA. Concurrence of supravalvular aortic stenosis and peripheral pulmonary stenosis in three generations of a family: a form of arterial dysplasia. Am J Med Genet 1993; 45:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/22\">",
"      Brook GJ, Keidar S, Boulos M, et al. Familial homozygous hypercholesterolemia: clinical and cardiovascular features in 18 patients. Clin Cardiol 1989; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/23\">",
"      Summers RM, Andrasko-Bourgeois J, Feuerstein IM, et al. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation 1998; 98:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/24\">",
"      Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/25\">",
"      Curran ME, Atkinson DL, Ewart AK, et al. The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell 1993; 73:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/26\">",
"      Metcalfe K, Rucka AK, Smoot L, et al. Elastin: mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet 2000; 8:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/27\">",
"      Morris CA, Mervis CB. Williams syndrome and related disorders. Annu Rev Genomics Hum Genet 2000; 1:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/28\">",
"      Ewart AK, Jin W, Atkinson D, et al. Supravalvular aortic stenosis associated with a deletion disrupting the elastin gene. J Clin Invest 1994; 93:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/29\">",
"      Ewart AK, Morris CA, Atkinson D, et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/30\">",
"      Meng X, Lu X, Li Z, et al. Complete physical map of the common deletion region in Williams syndrome and identification and characterization of three novel genes. Hum Genet 1998; 103:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/31\">",
"      Tassabehji M, Metcalfe K, Fergusson WD, et al. LIM-kinase deleted in Williams syndrome. Nat Genet 1996; 13:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/32\">",
"      Frangiskakis JM, Ewart AK, Morris CA, et al. LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 1996; 86:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/33\">",
"      Jones KL, Smith DW. The Williams elfin facies syndrome. A new perspective. J Pediatr 1975; 86:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/34\">",
"      Pagon RA, Bennett FC, LaVeck B, et al. Williams syndrome: features in late childhood and adolescence. Pediatrics 1987; 80:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/35\">",
"      Sharma BK, Fujiwara H, Hallman GL, et al. Supravalvar aortic stenosis: a 29-year review of surgical experience. Ann Thorac Surg 1991; 51:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/36\">",
"      Brown JW, Ruzmetov M, Vijay P, Turrentine MW. Surgical repair of congenital supravalvular aortic stenosis in children. Eur J Cardiothorac Surg 2002; 21:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/37\">",
"      Tani LY, Minich LL, Pagotto LT, Shaddy RE. Usefulness of doppler echocardiography to determine the timing of surgery for supravalvar aortic stenosis. Am J Cardiol 2000; 86:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/38\">",
"      Boxer RA, Fishman MC, LaCorte MA, et al. Diagnosis and postoperative evaluation of supravalvular aortic stenosis by magnetic resonance imaging. Am J Cardiol 1986; 58:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/39\">",
"      Stamm C, Kreutzer C, Zurakowski D, et al. Forty-one years of surgical experience with congenital supravalvular aortic stenosis. J Thorac Cardiovasc Surg 1999; 118:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/40\">",
"      Wessel A, Pankau R, Kececioglu D, et al. Three decades of follow-up of aortic and pulmonary vascular lesions in the Williams-Beuren syndrome. Am J Med Genet 1994; 52:297.",
"     </a>",
"    </li>",
"    <li>",
"     Obstruction of the left ventricular outflow tract. In: Cardiac Surgery of the Neonate and Infant, Jonas RA, Mayer JE, Hanley FL (Eds), WB Saunders, Philadelphia 1994. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40774/abstract/42\">",
"      van Son JA, Danielson GK, Puga FJ, et al. Supravalvular aortic stenosis. Long-term results of surgical treatment. J Thorac Cardiovasc Surg 1994; 107:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5777 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40774=[""].join("\n");
var outline_f39_52_40774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H965149\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPRAVALVAR AORTIC STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H965149\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5777|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/62/16355\" title=\"diagnostic image 1\">",
"      Supravalvar aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5777|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/11/43196\" title=\"table 2\">",
"      Causes LV outflow obstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33207?source=related_link\">",
"      Subvalvar aortic stenosis (subaortic stenosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40775="Treatment of refractory Kawasaki disease";
var content_f39_52_40775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of refractory Kawasaki disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40775/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/52/40775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD), also called mucocutaneous lymph node syndrome, is one of the most common vasculitides of childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1\">",
"     1",
"    </a>",
"    ]. It is typically a self-limited condition with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. However, cardiovascular complications may lead to significant morbidity and mortality in a sizeable percentage of affected children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major sequelae of KD, such as coronary artery aneurysms (CAA) leading to potential occlusion and cardiac ischemia, are dramatically decreased as a result of therapy with intravenous immune globulin (IVIG) therapy. Nonetheless, 10 to 15 percent of treated patients have persistent or recurrent fever indicative of ongoing vasculitis. Because the duration of fever correlates with risk of developing CAA, additional therapy is essential in patients with disease refractory to initial IVIG therapy.",
"   </p>",
"   <p>",
"    The treatment of refractory KD is discussed in this review. The initial treatment of KD, diagnosis, clinical manifestations, and cardiovascular sequelae are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 10 to 15 percent of patients with KD who are initially treated with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , fever persists or returns within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Persistent fever of any magnitude is generally assumed to be caused by ongoing vasculitis, although other causes of fever (such as reaction to IVIG therapy and intercurrent infection) should be considered. Barring extenuating circumstances, children are not usually retreated until at least 36 hours after the completion of their initial IVIG infusion, as fever before this time may represent a reaction to the medication.",
"   </p>",
"   <p>",
"    It is important for the clinician to remain alert to mild temperature elevations in children who have been treated for KD. The same cytokines that cause fever activate the inflammatory vasculitis that results in coronary artery damage. As an example, in one study of 378 patients, patients who remained febrile had an almost nine-fold increased risk of developing CAA abnormalities compared to those who responded to initial IVIG (12.2 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1\">",
"     1",
"    </a>",
"    ]. Unless an alternative explanation for persistent or recurrent fever is unambiguously demonstrated, children who are febrile more than 36 hours after the completion of their initial IVIG infusion require additional therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Therapeutic choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will respond to additional doses of IVIG therapy, but other patients with KD are resistant to IVIG therapy even after multiple doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. These patients are at greatest risk for developing CAA and long-term sequelae of the disease. Therapies effective in other forms of vasculitis, such as immunosuppressive agents (eg, glucocorticoids), and inhibitors of tumor necrosis factor (TNF) have been used in these patients.",
"   </p>",
"   <p>",
"    This was illustrated by an analysis of data from the Pediatric Health Information System that identified 4811 patients with KD between 2001 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/6\">",
"     6",
"    </a>",
"    ]. Fifteen percent of patients received repeat course(s) of IVIG. Other therapies for patients with refractory KD included intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (6 percent), oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (3 percent), and intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    , an anti-TNF agent, (1 percent). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Glucocorticoid therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'TNF inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When vasculitis is prolonged beyond three or four weeks, alternative diagnoses, such as chronic vasculitis (eg, polyarteritis nodosa), should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of IVIG resistance in patients with KD is about 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ]. For unclear reasons, however, this fraction can vary significantly, as demonstrated by a study from San Diego. The incidence of KD refractory to initial IVIG therapy increased to 38 percent in 2006 from a range of 10 to 20 percent between 1998 and 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/9\">",
"     9",
"    </a>",
"    ]. This increase did not appear to be related to any changes in the formulations of IVIG used. In comparison, in 2006, the incidence of refractory KD in Boston was 8 percent. The same IVIG brands and lots administered in San Diego to treat patients with KD were also used in Boston.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies have identified potential factors that predict which patients will require further therapy for refractory disease. The first study utilized the database of patients treated in 2003 and 2004 included in the 18th nationwide survey of KD in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/7\">",
"     7",
"    </a>",
"    ]. Of the 15,940 patients with KD, 20 percent did not respond to initial IVIG therapy. Risk factors associated with the need for retreatment included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment at or before the fifth day of illness (OR 1.89, 95% CI 1.66-2.15)",
"     </li>",
"     <li>",
"      Recurrent episodes of KD (OR 1.38, 95% CI 1.0-1.9)",
"     </li>",
"     <li>",
"      Male sex (OR 1.2, 95% CI 1.06-1.37)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonresponders compared to responders to initial IVIG therapy had a higher risk for coronary artery aneurysms (OR 10.38, 95% CI 6.98-15.45.) and giant coronary artery aneurysms (OR 54.06, 95% CI 12.84-227.65). Because this was a retrospective study, the timing of the initial treatment might have reflected the initial severity of illness. The high incidence of retreatment among children initially treated before the sixth day of illness could, thus, simply support the impression that severe vasculitis requires more aggressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other retrospective studies have reported that the following clinical factors increased the likelihood of patient nonresponsiveness to initial IVIG therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Young patient age, and in two of the studies, children less than one year of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Early diagnosis, with initial treatment at or before the 4th day of illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated C-reactive protein (&ge;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/10\">",
"       10",
"      </a>",
"      ] or &ge;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8\">",
"       8",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Elevated liver enzymes (aspartate aminotransferase, AST [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/9,10\">",
"       9,10",
"      </a>",
"      ], and alanine aminotransferase, ALT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8,9\">",
"       8,9",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &le;300,000/mm2",
"      </span>",
"     </li>",
"     <li>",
"      Elevated band count (8,25)",
"     </li>",
"     <li>",
"      Serum sodium &le;133",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      was reported as a risk factor in only one of the studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/10\">",
"       10",
"      </a>",
"      ], as was a low serum albumin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although scoring models based upon these risk factors have been developed to predict initial response to IVIG therapy, their sensitivity (range from 86 to 33 percent) and specificity (range from 87 to 62) are still not adequate for basing clinical decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Rather, the presence of one or more of these risk factors should alert the clinician to the increased likelihood that the patient might not respond adequately to the initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RETREATMENT WITH IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who remain febrile 36 hours after completion of their first dose of IVIG usually are treated with a second and perhaps even a third dose of IVIG (",
"    <a class=\"graphic graphic_algorithm graphicRef72236 \" href=\"mobipreview.htm?10/63/11262\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1\">",
"     1",
"    </a>",
"    ]. This practice is based upon the apparent dose-response effect of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=see_link&amp;anchor=H3#H3\">",
"     \"Kawasaki disease: Initial treatment and prognosis\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IVIG retreatment was first reported in a retrospective review of 13 patients from a single center [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/13\">",
"       13",
"      </a>",
"      ]. Eleven patients had initially received a total dose of 1.6",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      divided over four days, and the remaining two patients received a single IVIG dose of 2",
"      <span class=\"nowrap\">",
"       gm/kg.",
"      </span>",
"      After a second course of IVIG (1",
"      <span class=\"nowrap\">",
"       gm/kg),",
"      </span>",
"      fever and mucocutaneous involvement resolved within 48 hours in nine patients, and fever abated after a third course of IVIG (1",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      in two additional children.",
"     </li>",
"     <li>",
"      A retrospective survey of 378 children from 9 North American centers evaluated retreatment in 29 of 50 children who were refractory to their first course of IVIG (single dose of 1.6 to 2",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1\">",
"       1",
"      </a>",
"      ]. Twenty-four of the 29 retreated patients had normal echocardiograms after their first dose of IVIG, and these patients were further evaluated regarding clinical outcome. Seven patients received a second IVIG infusion of 1",
"      <span class=\"nowrap\">",
"       gm/kg;",
"      </span>",
"      fever resolved in five patients, and coronary aneurysms developed in four, including the two patients who remained febrile. Seventeen patients received a second IVIG infusion of 2",
"      <span class=\"nowrap\">",
"       gm/kg;",
"      </span>",
"      fever resolved in 15 patients, and coronary aneurysms developed in only one patient despite the fact that his fever had resolved after retreatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that the majority of patients with persistent fever after initial IVIG therapy will have resolution of their fever after retreatment with IVIG. It also appears that retreatment with higher doses of IVIG (hence a higher total cumulative dose of IVIG) decreased the risk of CAA.",
"   </p>",
"   <p>",
"    In the absence of data from prospective trials evaluating approaches to the treatment of children who fail initial treatment for KD, it is not possible to make firm recommendations. However, given the apparent dose-response effect of IVIG and its general safety, we suggest that children with persistent fever after an initial dose of IVIG should be retreated with a single infusion of IVIG (2",
"    <span class=\"nowrap\">",
"     gm/kg)",
"    </span>",
"    for a total cumulative IVIG dose of 4",
"    <span class=\"nowrap\">",
"     gm/kg.",
"    </span>",
"   </p>",
"   <p>",
"    Just as the mechanism of action of IVIG in KD is not understood, the reason that some patients with KD fail initial IVIG therapy is not clear. One possible explanation for the non-responsiveness to IVIG is the persistence of circulating inflammatory mediators, such as platelet-activating factor (PAF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/14\">",
"     14",
"    </a>",
"    ]. This was supported by an observation that children who did not respond initially to IVIG were more likely than those who responded initially to have a mutant allele in the plasma PAF acetylhydrolase gene. Those with the mutant allele had higher plasma enzymatic activity that could result in higher PAF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ALTERNATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even multiple doses of IVIG may incompletely control recalcitrant cases of KD. Thus, alternatives to IVIG retreatment are needed. These therapies have not been compared in controlled studies. However, the significantly increased risk of CAA in children who remain febrile after repeated IVIG therapy necessitates consideration of salvage therapies, provided that other explanations for fever (eg, medication reaction, arthritis, and intercurrent infection) have been excluded.",
"   </p>",
"   <p>",
"    Therapeutic alternatives include glucocorticoid therapy, inhibitors of tumor necrosis factor (TNF), and plasmapheresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefits of a short course of systemic glucocorticoids (also called corticosteroids) in patients with KD resistant to IVIG therapy were first described in case reports and series, and uncontrolled clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/2-5,15\">",
"     2-5,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report described four children with persistent KD despite therapy with IVIG who were treated with high-dose",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . All four patients responded with normalization of symptoms, and none had significant progression of CAA abnormalities or adverse events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Japanese case series, 63 of 411 patients (11 percent) did not respond to an initial IVIG infusion of 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      IVIG and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/16\">",
"       16",
"      </a>",
"      ]. Thirty-four of 44 nonresponding patients treated with intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three days) had persistent resolution of their fevers. The remaining 19 nonresponding patients were treated with an additional dose of IVIG, and 12 patients had resolution of fever. All patients who failed second line therapy were given another course of either methylprednisolone or IVIG. Overall, there were eight cases of CAA. One case occurred in a patient who responded to initial therapy, while the other seven cases occurred in patients who failed second line therapy. Five of the 10 patients who failed to respond to methylprednisolone, and two of the seven patients who failed to respond to a second dose of IVIG, developed CAA.",
"     </li>",
"     <li>",
"      In another trial, the safety and efficacy of pulsed-dose steroids versus additional doses of IVIG were compared in patients with IVIG-resistant KD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/2\">",
"       2",
"      </a>",
"      ]. In this trial, 35 of 262 patients (13 percent) did not respond to an initial infusion of 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of IVIG plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and were retreated with an additional dose of IVIG (1",
"      <span class=\"nowrap\">",
"       gm/kg).",
"      </span>",
"      Seventeen patients did not respond to the second dose of IVIG and were randomly assigned to receive either a single additional dose of IVIG (1",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      or pulsed dose glucocorticoids. Those who received steroids had a shorter duration of fever and lower overall medical costs. The incidence of CAA was high in both groups and did not differ significantly between the two (five of seven in the group retreated with IVIG and seven of nine in the steroid group). This study was limited by the small number of patients, and perhaps by the suboptimal dose of IVIG used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The glucocorticoid regimen most commonly used in patients who fail to respond to IVIG therapy is intravenous pulsed-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day administered daily for one to three days). We suggest that this regimen of methylprednisolone be given to patients who despite two doses of IVIG (total 4",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    demonstrate ongoing signs suggestive of active vasculitis (eg, persistent fever). Methylprednisolone is administered over two hours once daily until a full response (ie, resolution of fever and clinical manifestations of mucocutaneous inflammation) is obtained or the patient has received three doses of methylprednisolone. At that point, children who continue to have evidence of active vasculitis should be treated with one of the less-studied salvage therapies discussed below (eg, an anti-tumor necrosis factor-alpha (TNF-alpha) agent or plasmapheresis). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'TNF inhibition'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Plasmapheresis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk of CAA in children who fail IVIG and glucocorticoid therapy has led to a search for an alternative therapy in these patients. The following discussion includes several agents with the potential for causing more serious toxicity than either IVIG or glucocorticoids. All have been used in small numbers of children with refractory KD, so data on which to judge efficacy are quite limited.",
"   </p>",
"   <p>",
"    These agents should be used only in children with severe refractory KD who have not only failed initial standard therapy but also repeated infusions of IVIG and a course of glucocorticoid therapy. In addition, these therapies should be given under the supervision of a clinician with expertise in treating children with KD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     TNF inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-tumor necrosis factor-alpha (TNF-alpha) agents such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32790?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/31/35316?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    might be beneficial in KD, especially in view of the very elevated levels of TNF that characterize KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a small randomized multicenter trial, in which patients who failed an initial dose of IVIG were randomly selected to receive either an intravenous dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or a second dose of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/18\">",
"     18",
"    </a>",
"    ]. Fever resolved within 24 hours in 11 of 12 patients treated with infliximab, and 8 of 12 who received a second dose of IVIG. Two of the four patients who failed to respond to IVIG responded with fever resolution after crossing over to infliximab, and the one patient who initially failed to respond to infliximab responded to a second IVIG infusion. Progression of echocardiographic changes in coronary arteries was similar between the two groups. There were no severe adverse events directly attributed to treatment in either group. Transient hepatomegaly (but with normal serum alanine aminotransferase [ALT]) was observed in five patients from the infliximab group and one from the IVIG group. Three patients treated with infliximab developed low-titer antibodies to infliximab.",
"   </p>",
"   <p>",
"    In a retrospective review, patients who failed a first round of IVIG and were then treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    (n = 20) had significantly quicker resolution of fever (median 8 versus 10 days) and shorter length of hospitalization (5.5 versus 6 days) compared with those given a second dose of IVIG (n = 86) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/19\">",
"     19",
"    </a>",
"    ]. Coronary artery dimensions and adverse events were similar in the two groups.",
"   </p>",
"   <p>",
"    In a small observational study, 8 of 11 patients with refractory KD responded to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy with immediate fever resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/20\">",
"     20",
"    </a>",
"    ]. Four patients developed coronary artery lesions. Although proinflammatory cytokines (ie, soluble TNF receptor and IL-6), which were initially elevated, decreased with infliximab therapy in responsive patients, elevated markers of cell mediated vasculitis (ie, damage associated molecular pattern molecules and vascular endothelial growth factor) were not suppressed. In contrast, in patients who responded to IVIG, all cytokines decreased markedly after IVIG therapy. These results suggest that infliximab is effective in suppression of cytokine-mediated inflammation, but may not completely block vasculitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/31/35316?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    is a methyl xanthine compound that inhibits TNF-alpha messenger RNA transcription and is used in treatment of peripheral vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report compared patients treated initially with IVIG and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    alone to those in whom low-dose (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or high-dose (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day)",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/31/35316?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    was added [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/21\">",
"     21",
"    </a>",
"    ]. Coronary artery aneurysms were detected in 3 of 18 patients (17 percent) who received IVIG and aspirin alone, 2 of 18 patients (11 percent) who also received low-dose pentoxifylline, and none of 22 patients who also received high-dose pentoxifylline. No adverse effects were observed.",
"   </p>",
"   <p>",
"    Although further clinical trials are needed to determine the role of these agents in KD, anti-TNF therapy appears to hold promise for treatment of IVIG-resistant cases based upon its relative safety, rapidity of action, and reported efficacy compared with plasmapheresis,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Overall, a single intravenous dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    appears to work more rapidly and offer a more practical mode of administration than several oral doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/31/35316?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    . Accordingly, until additional data are available, our general preference is to treat children with persistent KD, despite two doses of IVIG and one to three doses of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , with a single dose of infliximab (5",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis is generally most effective in acute inflammatory conditions, whereas it seems to lack long-term benefit in chronic diseases. Thus, KD appears to be an ideal setting for this intervention. On the other hand, plasmapheresis is a technically complex and medically hazardous intervention, restricting its utility in a self-limited condition like KD. As an example, placement of a large bore central venous pheresis catheter in children with KD whose average age is two years is not a trivial undertaking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its limitations, rare case reports of dramatic responses of KD to plasmapheresis appeared in the literature during the time period in which glucocorticoids were viewed to be contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a non-randomized study of 75 children with KD who were unresponsive to two doses of IVIG, 27 children underwent plasmapheresis, and 48 received an additional dose of IVIG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/24\">",
"     24",
"    </a>",
"    ]. A lower percentage of children in the plasmapheresis group developed coronary artery lesions (11 versus 48 percent in the IVIG group).",
"   </p>",
"   <p>",
"    Nonetheless, in view of the risks associated with plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/25\">",
"     25",
"    </a>",
"    ], as well as the apparent efficacy of anti-TNF therapy, it is generally not recommended. Plasmapheresis only should be considered for children with active vasculitis despite multiple doses of IVIG, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and a trial of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of more potent immunosuppressive agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) in KD is not clear. These medications tend to be relatively toxic, with onsets of action that may be delayed for days or weeks. Because even patients with the most severe cases of KD generally have fever for less than three weeks, by the time standard therapies have been exhausted, few patients will remain ill enough to consider these immunosuppressive drugs.",
"   </p>",
"   <p>",
"    At least one group with considerable experience in the diagnosis and treatment of KD has reported treating severe, refractory cases with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/26\">",
"     26",
"    </a>",
"    ] and another group has reported success with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/27\">",
"     27",
"    </a>",
"    ]. Nonetheless, in view of the self-limited nature of KD, as well as the possibility that prolonged fever might be caused by something other than active vasculitis (eg, medication reaction, arthritis, intercurrent infection), situations in which these agents are necessary are extremely rare. When vasculitis is thought to be prolonged beyond three or four weeks, consideration should be given to an alternative diagnosis, such as systemic onset juvenile idiopathic arthritis or a chronic vasculitis, such as polyarteritis nodosa.",
"   </p>",
"   <p>",
"    Because the toxicities of these agents exceed the benefits in most patients with KD, we recommend careful consideration of all alternatives before their use in patients with refractory KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/25\">",
"     25",
"    </a>",
"    ]. New antiinflammatory agents, including biologic response modifiers, become available regularly.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/47/34551?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a B cell depleting monoclonal anti-CD20 antibody, was reported effective in a single case involving a child with KD refractory to IVIG and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/14/9446?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    , a novel anti-IL-6 monoclonal antibody, has also been used in several cases of IVIG-nonresponsive KD, although its effectiveness has been inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other agents, including antioxidants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/30\">",
"     30",
"    </a>",
"    ] and neutrophil-elastase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40775/abstract/31\">",
"     31",
"    </a>",
"    ], are being evaluated for the treatment of refractory KD, but their efficacy remains unclear. Ultimately, with more precise genetic characterization of children who develop the disease, as well as a better understanding of the factors that affect outcomes, it may be possible to tailor therapy to an individual child's needs. For now, until a perfectly effective and safe therapy is available for refractory KD, the search for better treatments is not likely to cease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 10 to 15 percent of patients initially treated with IVIG and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , fever persists or returns after IVIG treatment. Persistent fever of any magnitude after IVIG therapy usually indicates ongoing vasculitis, although other causes of fever should be excluded. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with KD who have persistent or recurrent fever after IVIG therapy are at significantly increased risk of developing coronary artery aneurysms (CAA). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with KD who have persistent fever 36 hours after completion of initial therapy, we recommend additional therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef72236 \" href=\"mobipreview.htm?10/63/11262\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Additional courses of IVIG and glucocorticoids have been best studied for this purpose.",
"     </li>",
"     <li>",
"      We suggest retreatment with a single dose of IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Additional dose(s) of IVIG can be administered prior to considering other medications in those patients who remain febrile, although the efficacy of a total dose of more than 4",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of IVIG has not been demonstrated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Retreatment with IVIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the subset of patients that appears to be resistant to IVIG therapy, we suggest treatment with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In our practice, we use pulsed-dose",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day administered on one to three consecutive days) once daily until a full response (eg, resolution of fever) is obtained or the patient has received three doses. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although various therapies effective in other forms of vasculitis have been used in patients with refractory KD, there are limited data concerning the risks and benefits of such an approach. The most promising of these appears to be",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"       infliximab",
"      </a>",
"      , a monoclonal antibody against tumor necrosis factor-alpha. In our practice, infliximab is given to children who have evidence of active vasculitis despite receiving two courses of IVIG (total 4",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      and one to three doses of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/1\">",
"      Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/2\">",
"      Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001; 43:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/3\">",
"      Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/4\">",
"      Venugopalan P, Jaya S, Al-Azri MA, Piopongco E. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003; 23:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/5\">",
"      Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001; 20:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/6\">",
"      Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/7\">",
"      Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/8\">",
"      Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/9\">",
"      Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/10\">",
"      Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/11\">",
"      Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008; 153:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/12\">",
"      Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/13\">",
"      Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/14\">",
"      Minami T, Suzuki H, Takeuchi T, et al. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 2005; 147:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/15\">",
"      Shetty AK, Homsi O, Ward K, Gedalia A. Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy. J Rheumatol 1998; 25:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/16\">",
"      Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008; 93:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/17\">",
"      Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992; 121:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/18\">",
"      Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008; 153:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/19\">",
"      Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011; 158:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/20\">",
"      Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009; 65:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/21\">",
"      Furukawa S, Matsubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994; 153:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/22\">",
"      Villain E, Kachaner J, Sidi D, et al. [Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins]. Arch Fr Pediatr 1987; 44:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/23\">",
"      Netter JC, Fries F, Rajon AM, et al. [Exchange transfusion in a case of Kawasaki syndrome]. Arch Fr Pediatr 1982; 39:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/24\">",
"      Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/25\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/26\">",
"      Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000; 105:E78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/27\">",
"      Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011; 30:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/28\">",
"      Sauvaget E, Bonello B, David M, et al. Resistant Kawasaki disease treated with anti-CD20. J Pediatr 2012; 160:875.",
"     </a>",
"    </li>",
"    <li>",
"     Sundel R, Harvard University, 2012, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/30\">",
"      Shen CT, Wang NK. Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin. Pediatr Cardiol 2001; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40775/abstract/31\">",
"      Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 2000; 181:1101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6408 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40775=[""].join("\n");
var outline_f39_52_40775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Therapeutic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RETREATMENT WITH IVIG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALTERNATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - TNF inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6408|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?10/63/11262\" title=\"algorithm 1\">",
"      Treatment of Kawasaki",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40776="Femoral shaft fractures in children";
var content_f39_52_40776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Femoral shaft fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Kimberly P Stone, MD, MS, MA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Klane White, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40776/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/52/40776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the femoral shaft are common childhood injuries and among the most common causes of hospitalization for pediatric orthopedic injuries. The strong blood supply of the femoral shaft allows for rapid healing and generally favorable outcomes. The treatment for femoral shaft fractures varies based on the child's age and injury with a trend towards operative stabilization.",
"   </p>",
"   <p>",
"    Femoral shaft fractures in pediatric patients are discussed here. Proximal femur fractures are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31975?source=see_link\">",
"     \"Hip fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distal femur fractures in children are discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral shaft fractures are among the most common diaphyseal fractures in children with an estimated annual incidence of 19 fractures per 100,000 children in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. They are also the most common pediatric fracture of the femur, accounting for up to 62 percent of all femur fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies have identified a bimodal age distribution for femoral shaft fractures with peaks in the toddler age group, where falls are the predominant cause of injury, and in the adolescent age group, where motor vehicle collisions cause most of the fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Across all age groups, boys have higher rates of femoral shaft fractures than girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality from a femur fracture has been estimated at 1 per 600 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/5\">",
"     5",
"    </a>",
"    ], but is most often due to associated injuries sustained as a result of high energy trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among hospitalized pediatric trauma patients, femur fractures are the most common orthopedic injury with an average length of stay of six days and an average hospital charge of $14,790 to $22,290 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Of the closed femur fractures in these study groups, 56 to 70 percent were located in the femoral shaft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femur is the largest bone in the body. It joins with the acetabulum of the pelvis proximally to form the hip joint and with the patella, tibia and fibula distally to form the knee joint. The pediatric femur can be divided anatomically into the proximal femur (made up of the femoral head, femoral neck, greater and lesser trochanter), the femoral shaft, and the distal femur (made up of the medial and lateral epicondyles, the medial and lateral condyles, and the trochlea) (",
"    <a class=\"graphic graphic_figure graphicRef78385 \" href=\"mobipreview.htm?26/53/27472\">",
"     figure 1",
"    </a>",
"    ). The femoral shaft can be further subdivided into the proximal third (subtrochanteric), middle third (midshaft), or distal third (supracondylar, intercondylar, condylar).",
"   </p>",
"   <p>",
"    Several muscles of the hip and knee joint insert, originate on, or cross the femoral shaft. With a femoral shaft fracture, these muscles contract causing shortening of the fractured femur. Some traction, either skeletal or skin, is often required initially to prevent further shortening before definitive treatment.",
"   </p>",
"   <p>",
"    The piriformis fossa is a particularly important femoral landmark (",
"    <a class=\"graphic graphic_figure graphicRef78385 \" href=\"mobipreview.htm?26/53/27472\">",
"     figure 1",
"    </a>",
"    ). The piriformis fossa lies at the base of the femoral neck and joins with the femoral shaft. It is the site of ascending vessels to the femoral neck which can be compromised during the surgical management of femoral shaft fractures. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Initial treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unlike the proximal femur, the femoral shaft has a strong vascular supply which supports rapid healing following injury. The vascular supply to the shaft is from both the endosteal and periosteal blood vessels. The medullary artery supplies the inner two-thirds of the femoral shaft, while the periosteal vessels supply the outer third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"     9",
"    </a>",
"    ]. This strong vascular supply also accounts for the significant blood loss that can accompany a femoral shaft fracture in an adult. Unlike adult femoral shaft fractures, observational studies in children have not found significant hemodynamic compromise associated with isolated pediatric femur fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral shaft is quite strong, and it is generally believed that high energy forces are required to fracture this bone. While this perception is generally true for transverse fractures, spiral femoral shaft fractures may result from fairly innocuous falls in ambulatory children, especially when they occur with a rotary force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. The specific mechanism of injury is most often related to the age of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infants and toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants and toddlers, falls and intentional trauma are among the leading causes of femoral shaft fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2-4,9,14\">",
"     2-4,9,14",
"    </a>",
"    ]. Femur fractures have traditionally been identified as red flags for child abuse among young children (age &lt;4 years). Evidence suggests that certain subgroups, most notably young children who are not yet walking, are at the highest risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/8,15,16\">",
"     8,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 139 children with femoral shaft fractures identified that 42 percent of non-walking children had a clinical presentation that was suspicious for abuse versus 3 percent of walking children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/8\">",
"       8",
"      </a>",
"      ]. However, specific investigation for child abuse occurred for only 38 children (27 percent).",
"     </li>",
"     <li>",
"      Another observational study of 42 children, aged one to five years, with isolated femoral shaft fractures who underwent social services investigation for inflicted injury found only one case of substantiated abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the authors noted that no discriminating features helped determine which injuries were intentional.",
"     </li>",
"     <li>",
"      Risk factors for abuse in 127 children under three years of age with a femur fracture were examined in an observational study from Canada. Of these patients, 24 were reported to child protective services by the initial examining physician, and the remaining were viewed as low risk for abuse based on retrospective chart review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/16\">",
"       16",
"      </a>",
"      ]. Ten of 60 children &lt;12 months of age with femur fractures were substantiated victims of abuse versus four of 67 of children one to three years of age (17 versus 6 percent). Femoral shaft fractures were the most common type of femur fracture in these patients. In addition to younger age, significant risk factors included nonambulatory status, delayed presentation, unwitnessed or inconsistent mechanism of injury, and other associated injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certainly, intentional trauma remains an important cause of femoral shaft fractures for all young children and warrants a high index of suspicion in those without a plausible explanation for their injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For toddlers to school-age children, falls remain the leading cause of femoral shaft fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2-4,7,8,15\">",
"     2-4,7,8,15",
"    </a>",
"    ]. In this age group, even relatively low-energy injuries, such as a fall from a low height or fall while running, may result in a femoral shaft fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As children reach their teenage years, motor",
"    <span class=\"nowrap\">",
"     vehicle/pedestrian",
"    </span>",
"    collisions, motor vehicle collisions, and sports-related injuries account for the majority of femoral shaft fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These results have been reproduced across several studies and in different countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with predisposing conditions, such as osteogenesis imperfecta, or other reasons for generalized osteopenia, such as cerebral palsy, spina bifida, or other neuromuscular conditions, are at higher risk for femoral shaft fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. These patients require appropriate studies to rule out femoral shaft fractures even when they present with an apparently minor injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pediatric femoral shaft fractures will not be subtle in their clinical presentation. The pediatric patient will have localized tenderness and swelling over the affected femoral shaft. Obvious deformity, shortening,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    crepitus on palpation are usually present. The physical examination should look for associated signs of a proximal femur fracture, such as pain in the hip joint",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a characteristic externally rotated leg position, as femoral shaft fractures may have associated proximal femur fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. The skin needs to be carefully inspected for signs of an open fracture.",
"   </p>",
"   <p>",
"    As with all fractures, a careful neurovascular exam distal to the site of the fracture before and after splinting is necessary to ensure that the displaced fracture has not damaged nerves or arteries.",
"   </p>",
"   <p>",
"    Thigh compartment syndrome as a result of a femoral shaft fracture is rare, but carries significant morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/18\">",
"     18",
"    </a>",
"    ]. Findings include tense thigh swelling and increasing pain, especially with passive movement of distal joints. Other classic symptoms of vascular occlusion (eg, pulselessness, pallor, paresthesias, and paralysis) may be seen with thigh compartment syndrome, as well, but are less common.",
"   </p>",
"   <p>",
"    Clinical evaluation of a child with a femoral shaft fracture must also identify other concomitant and life-threatening injuries when associated with high energy trauma (eg, high speed motor vehicle collision). In this circumstance, the incidence of associated injuries has been estimated to be 28 to 38 percent and accounts for the majority of morbidity, mortality, and cost associated with the care of children who suffer femoral shaft fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2,3,5,10\">",
"     2,3,5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"Waddell's triad\" was coined by Dr. Mercer Rang to describe a common pediatric injury pattern seen in young children who are hit by a motor vehicle when they run into the street. This pattern includes femur fracture, severe head injury, and thoracoabdominal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"     9",
"    </a>",
"    ]. These and other major life-threatening injuries have all been associated with femoral shaft fractures. Thus, a femur fracture is frequently associated with major multiple trauma and warrants a comprehensive assessment for multiple injuries in patients who have sustained high energy trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard anterior posterior (AP) and lateral plain radiographs of the entire affected femur, from hip joint to knee joint, are necessary to identify the fracture and provide pertinent information required for proper treatment (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68672 \" href=\"mobipreview.htm?20/14/20719\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78804 \" href=\"mobipreview.htm?21/13/21727\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based on the radiographic findings, the femoral shaft fracture can be evaluated for diaphyseal location (proximal, middle or distal third), configuration (transverse, oblique, spiral), angulation, amount of displacement, presence of comminution, and extent of shortening.",
"   </p>",
"   <p>",
"    Transverse femoral shaft fractures should alert the practitioner to carefully examine the radiographs of the femoral neck because shaft fracture is associated with femoral neck fracture, particularly in instances of high energy trauma. Thus, a clear radiograph of the femoral neck is mandatory.",
"   </p>",
"   <p>",
"    Children under two years of age in whom child abuse is suspected should undergo a skeletal survey to be evaluated for other bony injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link&amp;anchor=H8#H8\">",
"     \"Orthopedic aspects of child abuse\", section on 'Skeletal survey'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the femur represent significant injury, and almost always warrant early, urgent intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high energy trauma (eg, high speed motor vehicle collision) associated with femoral shaft fractures should be rigorously evaluated by standard trauma guidelines, including establishment of an airway with immobilization of the cervical spine, evaluation for pulmonary and circulatory compromise and placement of appropriate vascular access. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H8#H8\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Initial approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with an isolated femoral shaft fracture and no other serious injury, initial therapy consists of pain management and immobilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral opioid analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum initial dose: 10 mg) is most appropriate for initial pain control in children with femur fractures and should be given as soon as possible in the hemodynamically stabile child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once distal neurovascular function has been tested and evaluation for open wounds of the skin is complete, all femur fractures should be immobilized for comfort. Plaster, fiberglass, and various prefabricated splints are commonly used to provisionally stabilize the fracture.",
"   </p>",
"   <p>",
"    Splints work best when immobilizing both the hip and the knee. Consequently, splints placed laterally from the iliac crest to the ankle are quite effective. Splints can be further bolstered, or even substituted, by pillows, blankets or other types of bulky padding.",
"   </p>",
"   <p>",
"    Paramedical staff will frequently use traction splints to stabilize suspected femoral fractures in the field. These traction splints should be removed as soon as possible after arrival in the emergency department to prevent pressure ulcers from developing where the splints compress the skin. The traction splint should be replaced by a padded provisional splint as described above.",
"   </p>",
"   <p>",
"    Skeletal traction (traction applied to temporary pins drilled through bone), although commonly used in adults, is less frequently used in pediatric patients. Such traction is typically avoided initially because improper pin placement and excessive traction risk injury to growth plates. If a traction pin is deemed necessary, it should be placed by an experienced pediatric orthopedist in an operating room using sterile technique and x-ray guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a femoral shaft fracture in a child, especially a nonambulatory infant, with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the medical care team should ensure that children under two years of age with suspected intentional trauma undergo additional evaluation to determine the presence of other injuries once stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=see_link&amp;anchor=H8#H8\">",
"     \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All femoral shaft fractures must be evaluated by an orthopedic surgeon with appropriate pediatric expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive care for fractures of the femoral shaft can vary significantly, from short splint immobilization to open, operative treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. In general, treatment largely depends on the age of the patient, the patient's premorbid function, and the child's ability to tolerate an operation. Children less than five years of age, especially nonambulatory infants, are more commonly treated with nonoperative measures. The presence of an open fracture may also significantly alter the treatment plan. In addition, severely injured trauma patients may undergo nonoperative treatment until their hemodynamic status stabilizes so that they can tolerate the significant blood loss often associated with operative repair of femoral shaft fractures.",
"   </p>",
"   <p>",
"    Treatment options include: bracing, splinting, casting, traction, closed or open reduction with external frame fixation, and internal fixation with a plate or intramedullary rod (",
"    <a class=\"graphic graphic_table graphicRef67204 \" href=\"mobipreview.htm?1/9/1180\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children five years old and younger rarely require operative intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Infants &lt;12 months of age are easily treated with a splint. In neonates, soft cotton roll and a tongue depressor makes a nice splint of appropriate size and padding. The use of a Pavlik harness has also been described in the treatment of femoral shaft fractures in children &lt;4 months of age, and in selectively smaller infants up to six months of age (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51890 \" href=\"mobipreview.htm?5/54/5987\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Femur fractures in this age group usually heal within a month without long-term complications. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In larger infants up to a year of age, a traditional splint, as described previously, or, preferably, a hip spica cast is adequate. For fractures with &gt;3 cm of shortening, a course of skin or skeletal traction should be entertained.",
"   </p>",
"   <p>",
"    Older infants, toddlers and young children are most commonly treated in a hip spica cast (",
"    <a class=\"graphic graphic_picture graphicRef57513 \" href=\"mobipreview.htm?28/44/29382\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Closed reduction under sedation is required for fractures with more than 10 degrees of angulation. Again, fractures that are significantly shortened (&gt;3 cm) may require a few weeks of traction to reduce residual leg length discrepancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Operative intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;As children approach six years of age, intramedullary flexible rods may be considered in stable fracture patterns. Successful use of plates and external fixators has been described in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9,27\">",
"     9,27",
"    </a>",
"    ]. Extenuating circumstances, such as the multiply traumatized child, the presence of vascular injury, or other soft tissue constraints, are situations in which one of these modalities is more appropriate to implement. The expertise of an orthopedic surgeon well versed in the care of a child is paramount in these situations.",
"   </p>",
"   <p>",
"    By about age six, much stronger consideration is given to intramedullary fixation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67389 \" href=\"mobipreview.htm?14/28/14799\">",
"     image 4",
"    </a>",
"    ). The larger the child, the more appropriate it is to avoid a hip spica cast. Hip spica casts are much more difficult to manage in larger children, and older children are more capable of ambulating with crutches or a walker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/26\">",
"     26",
"    </a>",
"    ]. As such, in children 6 to 10 years of age, closed reduction and flexible intramedullary rod fixation are the treatments of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/22,28-31\">",
"     22,28-31",
"    </a>",
"    ]. There has been a recent trend toward the use of submuscular bridge plating, a construct which prevents shortening and is therefore more appropriate in highly comminuted, and therefore unstable, fracture patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After age eleven, the diameter of the femur will allow intramedullary fixation with a rigid locked rod, which is then the preferred treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/5,34\">",
"     5,34",
"    </a>",
"    ]. In younger children the traditional piriformis fossa starting point is associated with a small, but significant rate of osteonecrosis of the femoral head (average age 11.7 years). Consequently, a trochanteric starting point is used until skeletal maturity has been attained. Once skeletally mature, a piriformis fossa starting point is preferred for the adolescent population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/34\">",
"     34",
"    </a>",
"    ]. Traction followed by casting, and external fixation are appropriate and effective alternatives in this age group as well, but are, again, generally reserved for unusual circumstances as outlined previously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spica cast care can be daunting for families, particularly in the face of the psychological stress imposed by the injury itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients placed in a spica cast are best served by initial hospital admission for spica cast care and parental education as well as obtaining an appropriate car seat. This not only ensures proper cast care, but allows the patient's family to ease into the burden of caring for a child in a spica cast.",
"   </p>",
"   <p>",
"    Children who undergo operative repair or are treated in traction require admission to the hospital for ongoing monitoring to prevent neurovascular compromise or malunion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9,30,35,36\">",
"     9,30,35,36",
"    </a>",
"    ]. In most instances, children can be transitioned to a spica cast after three weeks of traction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant healing of femoral shaft fractures usually occurs by six weeks after treatment. As such, treatment by casting, splinting or traction rarely exceeds this time frame. Uncomplicated courses generally do not require more than a year of follow-up. Those with complications may require prolonged monitoring until skeletal maturity is reached.",
"   </p>",
"   <p>",
"    Treatment with an external fixator allows early mobilization, however, refracture or secondary fracture through the pin holes are well known complications after frame removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. As such, external fixators are left in place until solid fracture union is demonstrated radiographically to reduce the risk of refracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"     9",
"    </a>",
"    ]. This can be as long as four months after placement of the frame (10 to 16 weeks). Children with internal fixation, be it plating or intramedullary stabilization, are also easily mobilized. Removal of these implants is often performed six months or more after definitive treatment, if at all.",
"   </p>",
"   <p>",
"    Most children rehabilitate without much formal intervention. For children treated with internal or external fixation, early mobilization is facilitated by a physical therapist prior to discharge from the hospital, but typically, physical therapy is not required thereafter. Knee stiffness is uncommon, but can occur with flexible nails placed distally or with an external fixator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In these cases, physical therapy can be beneficial in regaining lost motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a rule, complications in the treatment of pediatric femur fractures are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/19,26,28,37\">",
"     19,26,28,37",
"    </a>",
"    ]. Many undesired outcomes can be overcome through the resiliency of childhood and growth. Complications from femur fractures can be broken down into two general categories: perioperative and remote. Perioperative complications are those encountered early on and are associated with the significant energy required to result in a femur fracture. Remote complications are typically the result of surgical oversight or altered biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Perioperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative complications include neurovascular injury, compartment syndrome, and infection. They are often associated with higher energy trauma such as motor vehicle accidents and falls from extreme heights:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve injuries are often transient, but can result in permanent nerve palsy.",
"     </li>",
"     <li>",
"      Vascular injuries warrant further evaluation with angiography or Doppler studies, and require urgent surgical treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infection typically presents approximately a week postoperatively, but can be delayed by several weeks (low grade infections may manifest as nonunion months after initial treatment) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications related to the altered pathophysiology and anatomy related to the fracture itself and the ensuing prolonged immobilization include fat embolus, venous thrombosis, and obstructive compression of the duodenum by the superior mesenteric artery (cast syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=see_link\">",
"     \"Superior mesenteric artery syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Remote",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remote complications such as shortening, overgrowth, leg length discrepancy, malunion (angular and rotational), and nonunion are relatively uncommon, and require intervention even less commonly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor discrepancies in length, rotation, and angular deformity are generally well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/36,43\">",
"       36,43",
"      </a>",
"      ]. In younger children, these abnormalities often resolve spontaneously with growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/44\">",
"       44",
"      </a>",
"      ]. In the rare case of symptomatic angular or rotational deformity, corrective osteotomy, ideally over an intramedullary device, is an effective treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leg length discrepancies are generally small. When the predicted leg length difference at maturity is &lt;2 cm, shoe inserts are the recommended treatment of choice. For predicted differences of 2 to 5 cm, contralateral epiphysiodesis (growth plate obliteration) can be performed prior to reaching skeletal maturity, resulting in the equalization of leg lengths. If the child has already reached skeletal maturity, then femoral shortening with intramedullary fixation is the recommended treatment of choice. Patients with a predicted leg length difference &gt;5 cm are typically treated with femoral lengthening via distraction osteogenesis.",
"     </li>",
"     <li>",
"      Nonunion in children is very uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9\">",
"       9",
"      </a>",
"      ]. It is typically associated with infections or cases in which significant soft tissue injury has occurred. Workup for infection should always occur in the face of fracture nonunion, including inflammatory markers such as white blood cell count, C-reactive protein (CRP), and estimated sedimentation rate (ESR). Treatment after placement of a solid intramedullary nail may include dynamization of the nail by removing the distal locking screws, thereby allowing compression of the fracture and increasing healing potential. In most other instances, open treatment with curettage of fibrous nonunion and bone grafting with either autograft (gold standard) or demineralized bone matrix are warranted. Rigid fixation with a plate or rigid nail is often required, but not mandatory, as in the adult population.",
"     </li>",
"     <li>",
"      Osteonecrosis of the femoral head has been reported in skeletally immature patients who have had a rigid femoral nail placed through the piriformis fossa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/45\">",
"       45",
"      </a>",
"      ]. The primary blood supply to the femoral head, via the lateral epiphyseal vessels, is interrupted by reaming through the piriformis fossa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/46\">",
"       46",
"      </a>",
"      ]. Consequently, use of the greater trochanter with appropriately engineered rigid nails is recommended in the skeletally immature child.",
"     </li>",
"     <li>",
"      Treatment with an external fixator may result in complications solely associated with this treatment option, and bears special mention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/39\">",
"       39",
"      </a>",
"      ]. Pin tract infections are very common with the use of external fixators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/39\">",
"       39",
"      </a>",
"      ]. These can be prevented with good pin care and the pre-drilling of pin holes, thus preventing thermal injury to the bone. Short courses of oral antibiotics can be helpful at keeping pin site infections at bay. Refracture through the original injury or fractures through pin holes after frame removal have also been reported to occur up to 20 percent of the time. Refracture has been attributed to premature frame removal. Because of these complications, the use of external fixation has been relegated to cases where soft tissue injury demands access to the wound and placement of internal fixation may raise concerns about deep infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/9,27\">",
"       9,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RETURN TO ACTIVITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with femur fractures have early limitations to their mobility. Physical therapy is required in patients who are old enough to navigate with crutches or a walker. A wheelchair is provided for all patients to facilitate longer distances. Once ambulatory, physical therapy is rarely necessary. Occasionally, knee stiffness can develop due to placement of flexible nails about the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40776/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Full weight bearing, with rare exception, is expected by six weeks after initiation of treatment. By three months, the majority of patients will be able to gradually return to normal activity, with full function typically restored by six months.",
"   </p>",
"   <p>",
"    Patients treated in an external fixator should be restricted from sports and high impact activities for an additional six to eight weeks after removal of the frame.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The femur is the largest bone in the body, and the most common site of diaphyseal fracture in children (",
"      <a class=\"graphic graphic_figure graphicRef78385 \" href=\"mobipreview.htm?26/53/27472\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pertinent anatomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Injury mechanism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants and toddlers, intentional trauma (ie, child abuse) is among the leading causes of femoral shaft fracture, especially in infants who are not yet walking. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infants and toddlers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Falls while playing or motor vehicle collisions are common mechanisms of injury in older children and adolescents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A femur fracture is frequently associated with major multiple trauma and warrants a comprehensive assessment for multiple traumatic injuries when a high energy force has occurred including a complete primary and secondary survey. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical and radiologic findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pediatric patient with a fractured femur will have localized tenderness and swelling over the affected femoral shaft. Obvious deformity, shortening,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crepitus on palpation are usually present. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard anterior posterior (AP) and lateral plain radiographs of the entire affected femur, from hip joint to knee joint, are necessary to identify the fracture and provide pertinent information required for proper treatment (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68672 \" href=\"mobipreview.htm?20/14/20719\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78804 \" href=\"mobipreview.htm?21/13/21727\">",
"       image 2",
"      </a>",
"      ). In the patient with femoral shaft fracture resulting from high energy trauma, a clear radiograph of the femoral neck is mandatory. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiographic assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children under two years of age in whom child abuse is suspected should undergo a skeletal survey to evaluate for other bony injuries. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link&amp;anchor=H8#H8\">",
"       \"Orthopedic aspects of child abuse\", section on 'Skeletal survey'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with an isolated femoral shaft fracture and no other serious injury, initial therapy consists of pain management and immobilization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All femoral shaft fractures must be promptly evaluated by an orthopedic surgeon with appropriate pediatric expertise. Definitive care for fractures of the femoral shaft can vary significantly, from short splint immobilization to open, operative treatment primarily depending on the age of the patient (",
"      <a class=\"graphic graphic_table graphicRef67204 \" href=\"mobipreview.htm?1/9/1180\">",
"       table 1",
"      </a>",
"      ). The presence of multiple serious injuries",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an open femur fracture are additional important modifying factors. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Indications for orthopedic consultation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Definitive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant healing of pediatric femoral shaft fractures usually occurs by six weeks after treatment. Full weight bearing, with rare exception, is expected at this time. By three months, the majority of patients will be able to gradually return to normal activity, with full function typically restored by six months. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Follow-up care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Return to activities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a femoral shaft fracture in a child, especially a nonambulatory infant, with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"       \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/1\">",
"      Hunter JB. Femoral shaft fractures in children. Injury 2005; 36 Suppl 1:A86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/2\">",
"      Loder RT, O'Donnell PW, Feinberg JR. Epidemiology and mechanisms of femur fractures in children. J Pediatr Orthop 2006; 26:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/3\">",
"      Rewers A, Hedegaard H, Lezotte D, et al. Childhood femur fractures, associated injuries, and sociodemographic risk factors: a population-based study. Pediatrics 2005; 115:e543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/4\">",
"      Hinton RY, Lincoln A, Crockett MM, et al. Fractures of the femoral shaft in children. Incidence, mechanisms, and sociodemographic risk factors. J Bone Joint Surg Am 1999; 81:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/5\">",
"      Galano GJ, Vitale MA, Kessler MW, et al. The most frequent traumatic orthopaedic injuries from a national pediatric inpatient population. J Pediatr Orthop 2005; 25:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/6\">",
"      Buess E, Kaelin A. One hundred pediatric femoral fractures: epidemiology, treatment attitudes, and early complications. J Pediatr Orthop B 1998; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/7\">",
"      Hedlund R, Lindgren U. The incidence of femoral shaft fractures in children and adolescents. J Pediatr Orthop 1986; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/8\">",
"      Schwend RM, Werth C, Johnston A. Femur shaft fractures in toddlers and young children: rarely from child abuse. J Pediatr Orthop 2000; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     Herring JA. Tachdijan's Pediatric Orthopaedics, 4th, Saunders, Philadelphia 2007. Vol 3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/10\">",
"      Lynch JM, Gardner MJ, Gains B. Hemodynamic significance of pediatric femur fractures. J Pediatr Surg 1996; 31:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/11\">",
"      Unal VS, Gulcek M, Unveren Z, et al. Blood loss evaluation in children under the age of 11 with femoral shaft fractures patients with isolated versus multiple injuries. J Trauma 2006; 60:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/12\">",
"      Ciarallo L, Fleisher G. Femoral fractures: are children at risk for significant blood loss? Pediatr Emerg Care 1996; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/13\">",
"      Pierce MC, Bertocci GE, Janosky JE, et al. Femur fractures resulting from stair falls among children: an injury plausibility model. Pediatrics 2005; 115:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/14\">",
"      Coffey C, Haley K, Hayes J, Groner JI. The risk of child abuse in infants and toddlers with lower extremity injuries. J Pediatr Surg 2005; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/15\">",
"      Blakemore LC, Loder RT, Hensinger RN. Role of intentional abuse in children 1 to 5 years old with isolated femoral shaft fractures. J Pediatr Orthop 1996; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/16\">",
"      Hui C, Joughin E, Goldstein S, et al. Femoral fractures in children younger than three years: the role of nonaccidental injury. J Pediatr Orthop 2008; 28:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/17\">",
"      Beaty JH. Fractures of the hip in children. Orthop Clin North Am 2006; 37:223.",
"     </a>",
"    </li>",
"    <li>",
"     Bucholz RW, Heckman JD, Court-Brown C. Rockwood and Green's Fractures in Adults, 6th, Lippincott Williams &amp; Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/19\">",
"      Poolman RW, Kocher MS, Bhandari M. Pediatric femoral fractures: a systematic review of 2422 cases. J Orthop Trauma 2006; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/20\">",
"      Buehler KC, Thompson JD, Sponseller PD, et al. A prospective study of early spica casting outcomes in the treatment of femoral shaft fractures in children. J Pediatr Orthop 1995; 15:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/21\">",
"      Hughes BF, Sponseller PD, Thompson JD. Pediatric femur fractures: effects of spica cast treatment on family and community. J Pediatr Orthop 1995; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/22\">",
"      Bopst L, Reinberg O, Lutz N. Femur fracture in preschool children: experience with flexible intramedullary nailing in 72 children. J Pediatr Orthop 2007; 27:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/23\">",
"      Stannard JP, Christensen KP, Wilkins KE. Femur fractures in infants: a new therapeutic approach. J Pediatr Orthop 1995; 15:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/24\">",
"      Podeszwa DA, Mooney JF 3rd, Cramer KE, Mendelow MJ. Comparison of Pavlik harness application and immediate spica casting for femur fractures in infants. J Pediatr Orthop 2004; 24:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/25\">",
"      Irani RN, Nicholson JT, Chung SM. Long-term results in the treatment of femoral-shaft fractures in young children by immediate spica immobilization. J Bone Joint Surg Am 1976; 58:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/26\">",
"      Ferguson J, Nicol RO. Early spica treatment of pediatric femoral shaft fractures. J Pediatr Orthop 2000; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/27\">",
"      Bar-On E, Sagiv S, Porat S. External fixation or flexible intramedullary nailing for femoral shaft fractures in children. A prospective, randomised study. J Bone Joint Surg Br 1997; 79:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/28\">",
"      Flynn JM, Hresko T, Reynolds RA, et al. Titanium elastic nails for pediatric femur fractures: a multicenter study of early results with analysis of complications. J Pediatr Orthop 2001; 21:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/29\">",
"      Flynn JM, Luedtke L, Ganley TJ, Pill SG. Titanium elastic nails for pediatric femur fractures: lessons from the learning curve. Am J Orthop (Belle Mead NJ) 2002; 31:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/30\">",
"      Flynn JM, Luedtke LM, Ganley TJ, et al. Comparison of titanium elastic nails with traction and a spica cast to treat femoral fractures in children. J Bone Joint Surg Am 2004; 86-A:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/31\">",
"      Ho CA, Skaggs DL, Tang CW, Kay RM. Use of flexible intramedullary nails in pediatric femur fractures. J Pediatr Orthop 2006; 26:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/32\">",
"      Sink EL, Gralla J, Repine M. Complications of pediatric femur fractures treated with titanium elastic nails: a comparison of fracture types. J Pediatr Orthop 2005; 25:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/33\">",
"      Hedequist D, Bishop J, Hresko T. Locking plate fixation for pediatric femur fractures. J Pediatr Orthop 2008; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/34\">",
"      Kanellopoulos AD, Yiannakopoulos CK, Soucacos PN. Closed, locked intramedullary nailing of pediatric femoral shaft fractures through the tip of the greater trochanter. J Trauma 2006; 60:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/35\">",
"      Malkawi H, Shannak A, Hadidi S. Remodeling after femoral shaft fractures in children treated by the modified blount method. J Pediatr Orthop 1986; 6:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/36\">",
"      Davids JR. Rotational deformity and remodeling after fracture of the femur in children. Clin Orthop Relat Res 1994; :27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/37\">",
"      Aronson J, Tursky EA. External fixation of femur fractures in children. J Pediatr Orthop 1992; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/38\">",
"      Blasier RD, Aronson J, Tursky EA. External fixation of pediatric femur fractures. J Pediatr Orthop 1997; 17:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/39\">",
"      Carmichael KD, Bynum J, Goucher N. Rates of refracture associated with external fixation in pediatric femur fractures. Am J Orthop (Belle Mead NJ) 2005; 34:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/40\">",
"      Wright JG, Wang EE, Owen JL, et al. Treatments for paediatric femoral fractures: a randomised trial. Lancet 2005; 365:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/41\">",
"      Kluger Y, Gonze MD, Paul DB, et al. Blunt vascular injury associated with closed mid-shaft femur fracture: a plea for concern. J Trauma 1994; 36:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/42\">",
"      Canale ST, Puhl J, Watson FM, Gillespie R. Acute osteomyelitis following closed fractures. Report of three cases. J Bone Joint Surg Am 1975; 57:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/43\">",
"      Wallace ME, Hoffman EB. Remodelling of angular deformity after femoral shaft fractures in children. J Bone Joint Surg Br 1992; 74:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/44\">",
"      Staheli LT. Femoral and tibial growth following femoral shaft fracture in childhood. Clin Orthop Relat Res 1967; 55:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/45\">",
"      Beaty JH, Austin SM, Warner WC, et al. Interlocking intramedullary nailing of femoral-shaft fractures in adolescents: preliminary results and complications. J Pediatr Orthop 1994; 14:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/46\">",
"      TRUETA J. The normal vascular anatomy of the human femoral head during growth. J Bone Joint Surg Br 1957; 39-B:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40776/abstract/47\">",
"      Narayanan UG, Hyman JE, Wainwright AM, et al. Complications of elastic stable intramedullary nail fixation of pediatric femoral fractures, and how to avoid them. J Pediatr Orthop 2004; 24:363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6549 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40776=[""].join("\n");
var outline_f39_52_40776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infants and toddlers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RADIOGRAPHIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonoperative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Operative intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Perioperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Remote",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RETURN TO ACTIVITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Injury mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical and radiologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6549|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/14/20719\" title=\"diagnostic image 1\">",
"      Transverse femur fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/13/21727\" title=\"diagnostic image 2\">",
"      Comminuted femoral shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/54/5987\" title=\"diagnostic image 3\">",
"      Neonatal femur fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/28/14799\" title=\"diagnostic image 4\">",
"      Intramedullary nail treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6549|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/53/27472\" title=\"figure 1\">",
"      Femoral anatomy child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6549|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/44/29382\" title=\"picture 1\">",
"      Spica cast application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6549|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/9/1180\" title=\"table 1\">",
"      Femoral shaft fracture treatment in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31975?source=related_link\">",
"      Hip fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/58/37799?source=related_link\">",
"      Superior mesenteric artery syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40777="Pelvic circulation";
var content_f39_52_40777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Pelvic circulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Illustration modified with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40777=[""].join("\n");
var outline_f39_52_40777=null;
var title_f39_52_40778="Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)";
var content_f39_52_40778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/52/40778/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/52/40778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H154973506\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria or fungi that translocate across intestinal mucosal surfaces. Patients with profound prolonged neutropenia are at particularly high risk for serious infections; profound prolonged neutropenia is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (HCT, particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"   </p>",
"   <p>",
"    Because neutropenic patients are unable to mount robust inflammatory responses, serious infection can occur with minimal symptoms and signs. In such patients, fever is often the only sign of infection. Infections in neutropenic patients can progress rapidly, leading to hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other life-threatening complications. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of empiric antibacterial and antifungal therapy for high-risk neutropenic adults presenting with fever will be reviewed here. The management of neutropenic fever in cancer patients at low risk for complications is discussed separately. An overview of neutropenic fever syndromes, the risk assessment of patients with neutropenic fever, and the diagnostic approach to patients presenting with neutropenic fever are presented elsewhere. The use of antimicrobial prophylaxis and colony stimulating factors to prevent infections in HCT recipients and patients with chemotherapy-induced neutropenia are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenic fever in children is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973513\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed for the management of fever in neutropenic patients with cancer, including hematopoietic cell transplant (HCT) recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2010 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973521\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973529\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in neutropenic patients is defined as a single oral temperature of &gt;38.3&deg;C (101&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. The definition of fever and appropriate methods for measuring body temperature are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H278237232#H278237232\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fever'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H86779646#H86779646\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973595\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of neutropenia varies from institution to institution but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and severe neutropenia is usually defined as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    over the next 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The risk of clinically important infection rises as the neutrophil count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is higher in those with a prolonged duration of neutropenia (&gt;7 days). For the purposes of this discussion,",
"    <strong>",
"     we will define neutropenia as an ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </strong>",
"   </p>",
"   <p>",
"    The",
"    ANC can be calculated by multiplying the total white blood cell (WBC) count by the percentage of polymorphonuclear cells (PMNs) and bands (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H981551211#H981551211\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of neutropenia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973748\">",
"    <span class=\"h1\">",
"     RISK OF SERIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation focuses on assessing the risk of serious complications. This risk assessment dictates the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"mobipreview.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low-risk patients are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction.",
"      </strong>",
"      This group of patients has been well studied in randomized trials and has been shown to be at low risk for serious complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"       1",
"      </a>",
"      ]. Most patients receiving chemotherapy for solid tumors are considered to be low-risk for complications requiring hospitalization or prolonging hospitalization.",
"     </li>",
"     <li>",
"      <strong>",
"       We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia.",
"      </strong>",
"      Other criteria that confer a high-risk status can be found in the Table (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"mobipreview.htm?39/26/40364\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      for &gt;7 days based on experience that such patients are the most likely to have life-threatening complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. However, formal studies to clearly differentiate between patients with an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are lacking. For the purposes of this discourse, we will combine these groups. Profound prolonged neutropenia (ie, ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days) is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative to using the clinical criteria described above is to use the Multinational Association for Supportive Care in Cancer (MASCC) risk index, which is a validated tool for measuring the risk for neutropenic fever-related medical complications (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/34/14881?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk assessment of patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973860\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with neutropenic fever, a reliable method for obtaining body temperature must be used and a mechanism for estimating the absolute neutrophil count (ANC) is mandatory. The temperature should be taken using oral or tympanic thermometry. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H86779646#H86779646\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Temperature measurement'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973874\">",
"    <span class=\"h2\">",
"     Risk of neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and their families should be instructed by their oncologist to inform healthcare providers in the triage setting about recent chemotherapy, and providers in the triage setting should ask cancer patients who do not offer this information about recent chemotherapy. The ANC can be estimated based upon the timing of the febrile episode following the first dose of the current cytotoxic chemotherapy or from a laboratory-based measurement of the ANC from a complete blood count (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Knowledge that the ANC reaches its nadir of &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at a median of 12 to 14 days from day one of chemotherapy can guide the clinician to the correct index of suspicion regarding the likelihood of neutropenia.",
"   </p>",
"   <p>",
"    Over 70 percent of cancer recipients who develop systemic therapy-related complications present to emergency triage facilities within four to six weeks of systemic anti-cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of a sensitive but non-specific historical indicator, receipt of systemic anti-cancer therapy within the preceding six weeks, has been advocated for use in emergency triage departments to identify patients who are likely to be neutropenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973912\">",
"    <span class=\"h2\">",
"     Risk of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, it is crucial to assess the risk of serious complications in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization. (See",
"    <a class=\"local\" href=\"#H154973748\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154973949\">",
"    <span class=\"h2\">",
"     Identification of SIRS and sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the signs and symptoms of infection may be significantly muted in neutropenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], an early part of the clinical assessment at triage should include a determination of the criteria for systemic inflammatory response syndrome (SIRS), sepsis (SIRS plus evidence for a focus of infection), severe sepsis (sepsis plus evidence for new end-organ dysfunction such as altered mental status, hypoperfusion, or hypoxia), or septic shock (severe sepsis plus hypotension refractory to adequate fluid resuscitation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients who have received systemic antineoplastic therapy within the previous six weeks and who present with SIRS should be presumed to have a neutropenic sepsis syndrome until proven otherwise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/9\">",
"     9",
"    </a>",
"    ]. SIRS is defined by the presence of &ge;2 of the following conditions: temperature &gt;38&deg;C or &lt;36&deg;C; heart rate",
"    <span class=\"nowrap\">",
"     &gt;90/minute;",
"    </span>",
"    respirations",
"    <span class=\"nowrap\">",
"     &gt;20/minute;",
"    </span>",
"    PaCO2 &lt;32 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with evidence of new organ dysfunction (altered mental status, hypotension, or hypoxia) should be managed emergently for severe sepsis. Patients with evidence for septic shock should be managed in a critical care hospital environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974079\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of patients presenting with neutropenic fever is summarized in the following Table (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"mobipreview.htm?23/55/24444\">",
"     table 2",
"    </a>",
"    ), and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974086\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974106\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in a neutropenic patient should be considered a medical emergency. Broad-spectrum antibacterials should be given as soon as possible and at full doses, adjusted for renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic function. In addition, the diagnostic evaluation should be obtained quickly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aim of empiric therapy is to cover the most likely and most virulent pathogens that may rapidly cause serious or life-threatening infection in neutropenic patients (",
"    <a class=\"graphic graphic_table graphicRef63465 \" href=\"mobipreview.htm?0/44/718\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. The following general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotics are usually administered empirically, but should always include appropriate coverage for suspected or known infections. Even when the pathogen is known, the antibiotic regimen should provide broad-spectrum empiric coverage for the possibility of other pathogens, unlike the treatment strategy adopted in many immunocompetent hosts.",
"     </li>",
"     <li>",
"      In high-risk patients, antibiotics should generally be administered intravenously in a hospital setting.",
"     </li>",
"     <li>",
"      Initial antibiotic selection should be guided by the patient's history, allergies, symptoms, signs, recent antibiotic use and culture data, and awareness of the susceptibility patterns of institutional nosocomial pathogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ideally, antibiotics should be bactericidal.",
"     </li>",
"     <li>",
"      Clinical response and culture and susceptibility results should be monitored closely, and therapy should be adjusted in a timely fashion in response to this information [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Febrile neutropenic patients should be monitored frequently with respect to vital signs (blood pressure, heart rate, respiratory rate, and temperature), performance status (the clinical burden of the neutropenic fever syndrome), and the ability to achieve adequate oral intake in the presence of oral or gastrointestinal mucositis. Temporarily holding administration of systemic chemotherapy should be considered during the management of the sepsis syndrome until the patient stabilizes. Attention to fluid and electrolyte management is important given the dehydrating effects of fever, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. Urine output of &gt;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour should be maintained.",
"   </p>",
"   <p>",
"    Afebrile neutropenic patients with new signs or symptoms that are consistent with infection should be evaluated and managed as if they are febrile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468185456\">",
"    <span class=\"h3\">",
"     Timing of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all febrile neutropenic patients, empiric broad-spectrum antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Antimicrobial therapy should be administered within",
"    <strong>",
"     60 minutes",
"    </strong>",
"    of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/9,12,18\">",
"     9,12,18",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H24660640#H24660640\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Timing of antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974271\">",
"    <span class=\"h3\">",
"     Spectrum of coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gram-positive bacteria are the most frequent pathogens identified during neutropenic fever episodes, it is important to cover broadly for gram-negative pathogens because of their virulence and association with sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Furthermore, gram-negative organisms continue to cause the majority of infections in sites outside of the bloodstream (eg, respiratory tract, biliary tract, gastrointestinal tract, urinary tract, and skin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/20\">",
"     20",
"    </a>",
"    ], and a rising number of infections are polymicrobial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Clinicians need to be aware of the current microbiology surveillance data from their own institution, which can vary widely from center to center and over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although anaerobic bacteria are present in abundance in the gastrointestinal tract, it is usually not necessary to include specific anaerobic antibiotic coverage in the initial empiric regimen. Anaerobic bacteremia occurred in only 3.4 percent of episodes in a large series of cancer patients from France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/21\">",
"     21",
"    </a>",
"    ], and anaerobic bacteria are often part of polymicrobial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Anaerobic coverage should be included in the regimens of patients with infections that are known or expected to be caused by anaerobes, as discussed below. (See",
"    <a class=\"local\" href=\"#H154974278\">",
"     'Initial regimen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As the duration of profound neutropenia increases, the risk of invasive fungal infections (eg, candidiasis, invasive aspergillosis) becomes substantial in patients with neutropenic fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H9533717#H9533717\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fungal pathogens'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H154974350\">",
"     'Addition of an antifungal agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology of infections in febrile neutropenic patients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H9533703#H9533703\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974278\">",
"    <span class=\"h2\">",
"     Initial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotics is driven by multiple factors, including the degree of immunocompromise, prior antibiotic and infection history, and local patterns of antibiotic resistance, and whether an agent is bactericidal or not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Some drugs, such as beta-lactams, exhibit time-dependent killing. When using beta-lactams, correct dosing intervals should be used to ensure that drug concentrations are greater than the minimal inhibitory concentration for the pathogen. Other antibiotics, such as aminoglycosides and fluoroquinolones, exhibit concentration-dependent killing and are important in the treatment of gram-negative sepsis.",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America (IDSA) recommends the following approach for the initial therapy of high-risk neutropenic patients with fever (",
"    <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"mobipreview.htm?40/56/41856\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]; we agree with this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of monotherapy with an anti-pseudomonal beta-lactam agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"       imipenem-cilastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      monotherapy has also been shown to be effective, and continues to be used at some cancer centers. However, many experts avoid ceftazidime monotherapy because of rising resistance rates among gram-negative bacteria and its limited activity against gram-positive bacteria, such as streptococci, compared to newer alternatives. The dosing of these agents for patients with normal renal function are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      &ndash; 2 g IV every eight hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      &ndash; 1 g IV every eight hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"       Imipenem-cilastatin",
"      </a>",
"      &ndash; 500 mg IV every six hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      &ndash; 4.5 g IV every six hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      &ndash; 2 g IV every eight hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other antibiotics (eg, aminoglycosides, fluoroquinolones,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) may be added to the initial regimen in patients with complicated presentations (eg, hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mental status changes), focal findings (eg, pneumonia or cellulitis) or if antimicrobial resistance is suspected or proven.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (or other agents that target gram-positive cocci) is",
"      <strong>",
"       not",
"      </strong>",
"      recommended as a standard part of the initial regimen but should be added in certain patients, such as those with suspected catheter-related infection, skin or soft tissue infection, pneumonia, or hemodynamic instability. (See",
"      <a class=\"local\" href=\"#H154974314\">",
"       'Addition of gram-positive coverage'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Modifications to the initial regimen should be considered for patients at risk for infection with antibiotic-resistant organisms, patients who are clinically unstable, and patients with positive blood cultures that are suggestive of a resistant infection. Risk factors for infections caused by resistant bacteria include previous infection or colonization by the organism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment in a hospital with high rates of resistance. (See",
"      <a class=\"local\" href=\"#H154974321\">",
"       'Modifications to the regimen'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H154974343\">",
"       'Antibiotic resistance'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we suggest that anaerobic coverage be included if there is evidence of necrotizing mucositis, sinusitis, periodontal cellulitis, perirectal cellulitis, intraabdominal infection (including neutropenic enterocolitis [typhlitis]), pelvic infection, or anaerobic bacteremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=see_link\">",
"     \"Typhlitis (neutropenic enterocolitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974285\">",
"    <span class=\"h3\">",
"     Comparisons of regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974293\">",
"    <span class=\"h4\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monotherapy with a beta-lactam agent with activity against Pseudomonas aeruginosa (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/36/38472?source=see_link\">",
"     imipenem-cilastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ) is frequently employed; clinical trials with ceftazidime, imipenem-cilastatin, or meropenem have demonstrated equivalent outcomes compared to two-drug regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In addition, fewer adverse events have generally been seen with monotherapy regimens compared with combination regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/27\">",
"     27",
"    </a>",
"    ]. The majority of the regimens evaluated provided coverage targeted at gram-negative bacilli, especially P. aeruginosa.",
"   </p>",
"   <p>",
"    Single drugs have also been compared with each other in various clinical trials of empiric therapy for patients with neutropenic fever, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter randomized trial, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      was compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      in 411 patients and the outcomes were similar for clinically defined and microbiologically defined infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another trial assessed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      versus imipenem in 251 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/29\">",
"       29",
"      </a>",
"      ]. In an intent-to-treat analysis, the response to treatment in the two groups was comparable (75 versus 68 percent, respectively) as was the side effect profile.",
"     </li>",
"     <li>",
"      A multicenter open-label randomized trial compared the efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      in 528 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/30\">",
"       30",
"      </a>",
"      ]. On multivariate analysis, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      -tazobactam was associated with greater treatment success (odds ratio, 1.65, 95% CI 1.04-2.64).",
"     </li>",
"     <li>",
"      A meta-analysis of clinical trials showed increased mortality among patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      compared with other beta-lactam antibiotics, particularly in those with neutropenic fever; both groups included patients who received either monotherapy or combination therapy of a beta-lactam plus a non-beta-lactam antibiotic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/31\">",
"       31",
"      </a>",
"      ]. However, in a subsequent meta-analysis performed by the United States Food and Drug Administration (FDA), which included 50 more trials than the original meta-analysis as well as patient-specific information, there was no difference in mortality between patients who received cefepime and patients who received other antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Accordingly, the IDSA guidelines continue to recommend cefepime as a suitable option [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One concern about monotherapy is the possibility that increasing rates of antibiotic resistance in a number of pathogens may reduce the efficacy of this strategy. Single agents, especially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , may actually promote the outgrowth of resistant organisms in this group of patients who require frequent antibiotic administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/34\">",
"     34",
"    </a>",
"    ]. It is therefore important to maintain vigilance for the emergence of antibiotic resistance locally that may necessitate a change in antibiotic practices. (See",
"    <a class=\"local\" href=\"#H154974343\">",
"     'Antibiotic resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974300\">",
"    <span class=\"h4\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous combination antibiotic regimens have been studied as initial empiric therapy in neutropenic fever, but none has been shown to be clearly superior to others or to monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. One approach is to use an extended-spectrum beta-lactam (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ) in combination with an aminoglycoside. Other examples of combination regimens include double beta-lactams or a beta-lactam and a fluoroquinolone. A meta-analysis of eight randomized controlled trials that compared",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"      ciprofloxacin",
"     </a>",
"     /beta-lactam",
"    </span>",
"    combinations to",
"    <span class=\"nowrap\">",
"     aminoglycoside/beta-lactam",
"    </span>",
"    regimens for the empiric therapy of neutropenic fever demonstrated similar overall efficacy for clinical cure and all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/36\">",
"     36",
"    </a>",
"    ]. Double beta-lactams are usually avoided because of overlapping toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974307\">",
"    <span class=\"h3\">",
"     Penicillin-allergic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with a history of allergy to penicillin tolerate cephalosporins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    ). However, those with a history of an immediate-type hypersensitivity reaction (eg, hives",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchospasm) should not receive beta-lactams or carbapenems. Alternative empiric regimens for such patients include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    <strong>",
"     or",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, fluoroquinolones should not be used in patients who have received them recently (including those receiving a fluoroquinolone for neutropenic prophylaxis). The decision of which alternative regimen to use in penicillin-allergic patients should be made based upon the susceptibility patterns of bacteria (especially gram-negative bacilli) at the individual institution as well as the patient&rsquo;s previous microbiologic data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974314\">",
"    <span class=\"h2\">",
"     Addition of gram-positive coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine addition of gram-positive antibiotic coverage to the initial empiric antibiotic regimen has not been associated with significant clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. A meta-analysis of seven randomized trials found that addition of gram-positive antibiotic coverage to standard empiric therapy did not reduce all-cause mortality in patients with cancer and neutropenic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in febrile neutropenic patients with skin and soft tissue infections who had a higher incidence of proven gram-positive bacteremia compared with patients with other infections (31 versus 17 percent), the addition of empiric",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    did not improve outcomes and was associated with increased toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of promoting resistance among enterococci and Staphylococcus aureus is an important reason to avoid empiric vancomycin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (or other agents that target gram-positive cocci) is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a standard part of the initial regimen, but gram-positive coverage should be added in patients with any of the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic instability or other signs of severe sepsis",
"     </li>",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Positive blood cultures for gram-positive bacteria while awaiting speciation and susceptibility results",
"     </li>",
"     <li>",
"      Suspected central venous catheter (CVC)-related infection (eg, chills or rigors during infusion through a CVC",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cellulitis around the catheter entry site)",
"     </li>",
"     <li>",
"      Skin or soft tissue infection",
"     </li>",
"     <li>",
"      Severe mucositis in patients who were receiving prophylaxis with a fluoroquinolone lacking activity against streptococci and in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      is being used as empiric therapy. Addition of gram-positive coverage is recommended in this situation because of the increased risk of Streptococcus viridans infections, which can result in sepsis and the acute respiratory distress syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1,43-46\">",
"       1,43-46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric gram-positive coverage is particularly important for patients who are colonized with methicillin-resistant S. aureus (MRSA),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcus, or penicillin- or ceftriaxone-resistant streptococci who become hemodynamically unstable or develop bacteremia with gram-positive cocci.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is used most commonly when an agent with specific gram-positive activity is indicated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is an alternative for patients intolerant of vancomycin. However, a concern with linezolid is that it may cause myelosuppression, typically after two or more weeks of therapy. Whether myelosuppressive effects can be seen earlier in patients receiving chemotherapy remains unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter randomized trial of 611 febrile neutropenic patients compared the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients with proven or suspected infection due to a gram-positive pathogen were randomly assigned to receive linezolid (600 mg IV every 12 hours) or vancomycin (1 g IV every 12 hours) for 10 to 28 days. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical success rates seven days after completion of therapy were equivalent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (87 versus 85 percent, respectively).",
"     </li>",
"     <li>",
"      Mortality rates at 16 days after completion of therapy were similar (17 of 304 patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      [6 percent] and 23 of 301 [8 percent] who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Drug-related adverse events occurred more frequently in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      group (24 versus 17 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with documented gram-positive infections, those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      defervesced more quickly than those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (5.9 versus 9.1 days); there was no difference in time to defervescence among patients without documented infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is another alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , but it has been less well studied and should",
"    <strong>",
"     not",
"    </strong>",
"    be used for pulmonary infections because it is inactivated by surfactant and therefore does not achieve sufficiently high concentrations in the respiratory tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H41849395#H41849395\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974321\">",
"    <span class=\"h2\">",
"     Modifications to the regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications to the antimicrobial regimen during the course of neutropenic fever can be made based upon the following principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial treatment regimen should be modified based upon clinical and microbiologic data.",
"     </li>",
"     <li>",
"      Unexplained persistent fever in a patient who is otherwise stable rarely necessitates an empiric adjustment to the initial antibacterial regimen. However, if an infection is identified, the regimen should be adjusted accordingly.",
"     </li>",
"     <li>",
"      Documented infections (based on clinical findings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      microbiologic data) should be treated with antibiotics that are appropriate for the site and susceptibility patterns of organisms that are isolated.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      or other gram-positive coverage was started initially, it may be stopped after two to three days if there is no evidence of a gram-positive infection. Vancomycin overuse has been associated with the development of resistance (eg, vancomycin-resistant Enterococcus spp).",
"     </li>",
"     <li>",
"      Patients who are or become hemodynamically unstable after initial doses of a standard antimicrobial regimen for neutropenic fever should have their regimen broadened to include coverage for resistant gram-negative, gram-positive, and anaerobic bacteria, as well as fungi. (See",
"      <a class=\"local\" href=\"#H154974343\">",
"       'Antibiotic resistance'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H154974350\">",
"       'Addition of an antifungal agent'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Empiric antifungal coverage should be considered in high-risk patients who have persistent fever after four to seven days of a broad-spectrum antibacterial regimen and no identified source of fever. (See",
"      <a class=\"local\" href=\"#H154974350\">",
"       'Addition of an antifungal agent'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Oral ulcerations may be due to herpes simplex virus or Candida spp. Thus, addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      may be warranted if these findings are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with diarrhea, if there are abdominal signs, empiric therapy of Clostridium difficile can be instituted while assays are pending. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=see_link\">",
"       \"Clostridium difficile in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423440041\">",
"    <span class=\"h3\">",
"     Persistent fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median time to defervescence following the initiation of empiric antibiotics in patients with hematologic malignancies, including hematopoietic cell transplant (HCT) recipients, is five days, in contrast to only two days for patients with solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. As stated above, modification of the initial antibacterial regimen is",
"    <strong>",
"     not",
"    </strong>",
"    needed for persistent fever alone. However, patients who remain febrile after the initiation of empiric antibiotics should be reevaluated for possible infectious sources. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management algorithms have been developed for the reassessment of neutropenic patients with persistent fever after two to four days (",
"    <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"mobipreview.htm?0/14/225\">",
"     algorithm 2",
"    </a>",
"    ), and after four or more days (",
"    <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"mobipreview.htm?11/47/12017\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. Key factors in the management of patients with persistent fever include whether the patient is clinically stable, whether there is an identified site of infection, and when the patient is expected to recover from neutropenia. Consideration should be given to the addition of empiric antifungal therapy, as described below. (See",
"    <a class=\"local\" href=\"#H154974350\">",
"     'Addition of an antifungal agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974343\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing frequency of antibiotic-resistant organisms is a major concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The patient&rsquo;s risk for the following resistant organisms should be considered when choosing an empiric regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among gram-positive organisms, pathogens with acquired resistance include coagulase-negative staphylococci, MRSA,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococci (VRE), and penicillin- and ceftriaxone-resistant Streptococcus pneumoniae and other streptococci.",
"     </li>",
"     <li>",
"      Gram-positive organisms that have intrinsic resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (Leuconostoc,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      , and Pediococcus spp).",
"     </li>",
"     <li>",
"      Multidrug-resistant gram-negative bacilli, such as P. aeruginosa, Escherichia coli, and Citrobacter, Acinetobacter and Stenotrophomonas spp [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/17\">",
"       17",
"      </a>",
"      ]. The use of fluoroquinolones for prophylaxis has contributed to the emergence of antibiotic resistance.",
"     </li>",
"     <li>",
"      The presence of extended-spectrum beta-lactamases (ESBL), plasmid-mediated AmpC-type beta-lactamases, and carbapenemase-producing bacteria (eg, Klebsiella pneumoniae carbapenemase [KPC]) can severely limit treatment options [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/18,52\">",
"       18,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for infections with resistant bacteria include previous infection or colonization by the organism, recent use of antibacterial agents (eg, for prophylaxis), and treatment in a hospital with high rates of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. It is important to be aware of institutional resistance patterns since a variety of nosocomial outbreaks involving cancer patients have been reported. Some centers have reported an increased incidence of resistant pathogens with the routine use of prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Antibiotic history, recent culture results, exposure to prophylactic antibiotics, and the susceptibility patterns for organisms in the institution should be used to help guide selection of initial antibiotic therapy.",
"   </p>",
"   <p>",
"    Strategies to reduce drug resistance include limiting prophylaxis, using targeted therapy when feasible, discontinuing unneeded empiric therapies (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) when cultures remain negative, and initiation of antibiotic stewardship programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H154974314\">",
"     'Addition of gram-positive coverage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following antibiotics can be used when resistant infections are suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       MRSA",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      ; daptomycin should be avoided in patients with pneumonia because it does not achieve sufficiently high concentrations in the respiratory tract. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H41849395#H41849395\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Other agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       VRE",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"       daptomycin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=see_link\">",
"       \"Treatment of enterococcal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       ESBL-producing gram-negative bacilli",
"      </strong>",
"      &ndash; A carbapenem (eg, imipenem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link&amp;anchor=H14#H14\">",
"       \"Extended-spectrum beta-lactamases\", section on 'Treatment options'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=see_link&amp;anchor=H10#H10\">",
"       \"Gram-negative bacillary bacteremia in adults\", section on 'Extended-spectrum beta-lactamases'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Carbapenemase-producing bacteria, including Klebsiella pneumoniae carbapenemase (KPC)",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       Colistin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=see_link&amp;anchor=H8#H8\">",
"       \"Carbapenemases\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=see_link&amp;anchor=H11#H11\">",
"       \"Gram-negative bacillary bacteremia in adults\", section on 'Carbapenem resistance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974350\">",
"    <span class=\"h2\">",
"     Addition of an antifungal agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974358\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An empiric antifungal agent should be added after four to seven days in high-risk neutropenic patients who are expected to have a total duration of neutropenia &gt;7 days who have persistent or recurrent fever and in whom reassessment does not yield a cause (",
"    <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"mobipreview.htm?11/47/12017\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. The rationale for this approach is that undiagnosed fungal infection was found in early studies in many patients who died during prolonged neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The incidence of fungal infection (especially those caused by Candida or Aspergillus spp) rises after patients have experienced more than seven days of persistent neutropenic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who are clinically unstable or have a suspected fungal infection, antifungal therapy should be considered even earlier than what is recommended for empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ongoing question is whether all high-risk neutropenic patients with persistent fever need to receive empiric antifungal therapy, since fungal infection is not documented in most patients. The following observations provide limited support for this practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an autopsy study of patients who died after prolonged neutropenic fever between 1966 and 1975, 69 percent of patients had evidence of systemic fungal infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/58\">",
"       58",
"      </a>",
"      ]. It should be noted that over one-half of the patients in this early series had Candida infections, which may have been effectively prevented with antifungal prophylaxis strategies. For example, in one trial, fungal infections were documented in only 1 percent of persistent fevers in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Resolution of fever occurs in approximately 40 to 50 percent of patients given antifungal therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/57,58,60,61\">",
"       57,58,60,61",
"      </a>",
"      ]. However, this does not prove that the patient had an occult fungal infection. Since slow responses to empiric antibacterial therapy are frequent in high-risk patients, the defervescence noted in temporal association with antifungal therapy may be explained by antibacterial therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974365\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent for empiric antifungal therapy depends upon which fungi are most likely to be causing infection, as well as the toxicity profiles and cost (",
"    <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"mobipreview.htm?11/47/12017\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients who have not been receiving antifungal prophylaxis, Candida spp are the most likely cause of invasive fungal infection. In patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis, fluconazole-resistant Candida spp (eg, C. glabrata and C. krusei) and invasive mold infections, particularly Aspergillus spp, are the most likely causes.",
"   </p>",
"   <p>",
"    The 2010 IDSA guidelines for empiric antifungal therapy recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate, a lipid formulation of amphotericin B,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    as suitable options for empiric antifungal therapy in neutropenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence to support the use of each of these agents is presented below. (See",
"    <a class=\"local\" href=\"#H154974379\">",
"     'Studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We favor the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For persistently febrile patients who have not been receiving antifungal prophylaxis and who have no obvious site of infection, such as pulmonary nodules, we favor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      (or another echinocandin) since Candida spp is a likely cause in such patients and the echinocandins provide excellent coverage for Candida spp and are well tolerated.",
"     </li>",
"     <li>",
"      For persistently febrile patients with pulmonary nodules or nodular pulmonary infiltrates, invasive mold infection should be strongly suspected and treated. Prompt assessment frequently requires bronchoscopy with bronchoalveolar lavage with cultures, stains, and Aspergillus galactomannan antigen testing to distinguish bacterial from mold pathogens, while simultaneously initiating antibacterial and anti-mold therapy until the specific etiology is established. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=see_link&amp;anchor=H1064486494#H1064486494\">",
"       \"Diagnosis of invasive aspergillosis\", section on 'Approach to diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      or a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      are preferred in patients with pulmonary findings suggestive of an invasive mold infection due to higher failure rates with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      in preventing and treating invasive aspergillosis, which is the most common cause of mold infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/62\">",
"       62",
"      </a>",
"      ]. Current data are insufficient to conclusively determine whether voriconazole or a lipid formulation of amphotericin B is optimal; the choice of the initial antifungal agent may vary based on an institution's experience (ie, epidemiology and susceptibility patterns) and patient risks for specific mold infections (eg, Aspergillus versus the agents of mucormycosis). Most experts prefer voriconazole if aspergillosis is thought to be most likely, but if mucormycosis is suspected, an amphotericin B formulation should be given since voriconazole has no activity against the agents of mucormycosis. It is important to note that at most centers, aspergillosis accounts for the majority of invasive fungal infections in neutropenic patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link&amp;anchor=H564717505#H564717505\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link&amp;anchor=H20422806#H20422806\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For persistently febrile patients who have been receiving anti-mold prophylaxis, a different class of antifungal agent with activity against molds should be used for empiric therapy. For example, if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      has been used for prophylaxis, an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation should be used. We favor a lipid formulation of amphotericin B rather than amphotericin B deoxycholate in order to minimize toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to remember that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    and other echinocandins are not active against Cryptococcus spp, Trichosporon spp, and filamentous molds other than Aspergillus spp, such as Fusarium spp. In addition, some yeasts can demonstrate relative resistance to these drugs (Candida parapsilosis, C. rugosa, C. guilliermondii, and non-candidal yeasts). Failure of caspofungin to prevent aspergillosis has also been reported, even though it has in vitro activity against Aspergillus spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/63\">",
"     63",
"    </a>",
"    ]. Moreover, the clinical efficacy of the echinocandins for endemic fungi (Histoplasma, Blastomyces, Coccidioides spp) has not been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1785?source=see_link\">",
"     \"Infections due to Trichosporon species and Blastoschizomyces capitatus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974372\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of the various antifungal agents recommended above is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &ndash; Loading dose of 70 mg IV on day one, then 50 mg IV once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      &ndash; Loading dose of 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours on day one, followed by 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"       Amphotericin B lipid complex",
"      </a>",
"      &ndash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      &ndash; 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974379\">",
"    <span class=\"h3\">",
"     Studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been made about each of the agents used for empiric antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974386\">",
"    <span class=\"h4\">",
"     Amphotericin B formulations",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate has historically been the most common agent given. In a randomized trial of patients with persistent neutropenic fever,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    was compared with amphotericin B deoxycholate",
"    <em>",
"    </em>",
"    using a composite of five end points: survival, resolution of fever during neutropenia, resolution of preexisting fungal infection, prevention of breakthrough fungal infection, and absence of premature discontinuation of the drug because of toxicity or lack of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/64\">",
"     64",
"    </a>",
"    ]. Both drugs performed similarly in terms of survival (93 versus 90 percent) and resolution of fever (58 percent each), but the liposomal preparation was associated with significant reductions in breakthrough fungal infections; infusion-related fever, chills, or rigors; and nephrotoxicity. The lipid formulations of amphotericin B have replaced amphotericin B deoxycholate in most centers due to toxicity considerations, but they are more costly. Amphotericin B deoxycholate should be avoided in patients with antecedent renal disease and in those receiving other nephrotoxic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974401\">",
"    <span class=\"h4\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared the echinocandin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    in 1095 patients with persistent neutropenic fever despite four days of empiric antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/65\">",
"     65",
"    </a>",
"    ]. The overall success rates (34 and 34 percent), and the rates of breakthrough fungal infections and resolution of fever were similar in both arms.",
"    <br/>",
"    <br/>",
"    In the small subset of patients who had a fungal infection at baseline (only 27 per group), a successful outcome was significantly more likely with caspofungin than liposomal amphotericin (52 versus 26 percent). Caspofungin was also associated with a significantly higher rate of survival seven days after the completion of therapy (93 versus 89 percent) and was significantly less likely to be associated with nephrotoxicity (2.6 versus 11.5 percent), infusion-related events (35 versus 52 percent), or cessation of therapy for drug-related adverse events (5 versus 8 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    are other echinocandins, but they have not been adequately studied or approved by the FDA for patients with neutropenic fever. Micafungin appeared to be effective in small studies in patients with neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. These agents can be used as alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    when caspofungin is not available, since the spectrum and antifungal activity of all three agents is similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Echinocandins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9338?source=see_link\">",
"     \"Pharmacology of echinocandins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974408\">",
"    <span class=\"h4\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international open-label, randomized trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in 837 neutropenic patients with persistent fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/68\">",
"     68",
"    </a>",
"    ]. Mortality was similar in both groups. There was a trend toward a better response with liposomal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    compared with voriconazole in four of five composite endpoints, including overall response (31 versus 26 percent), but voriconazole was associated with significantly fewer documented breakthrough fungal infections (2 versus 5 percent). Voriconazole was associated with fewer infusion-related adverse effects and less nephrotoxicity, but with more cases of transient visual changes and hallucinations.",
"    <br/>",
"    <br/>",
"    The results of this study are difficult to interpret and may have been affected by the open-label design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/69\">",
"     69",
"    </a>",
"    ]. More patients had voriconazole stopped for perceived lack of efficacy (ongoing fevers), although fevers persisted equally in the liposomal amphotericin B group. The FDA reviewed the results of the trial along with additional information from the sponsor and recommended not to approve a licensed indication for voriconazole for empiric antifungal treatment, since voriconazole did not fulfill the criterion for noninferiority compared with liposomal amphotericin B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/63,70\">",
"     63,70",
"    </a>",
"    ]. Whether the failure to meet the statistical definition of noninferiority reflects a true difference in efficacy between voriconazole and liposomal amphotericin B or a problem in the study design awaits further clinical trials.",
"   </p>",
"   <p>",
"    Nevertheless, the IDSA guidelines recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    as an option for empiric antifungal therapy due to its proven efficacy against Candida and Aspergillus spp infections, the chief fungal pathogens in patients with neutropenic fever, and the lower risk of serious toxicity compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974415\">",
"    <span class=\"h4\">",
"     Other azoles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       Posaconazole",
"      </a>",
"      &ndash; Posaconazole is a broad-spectrum triazole that has been approved by the FDA for the prophylaxis of fungal infections in neutropenic patients and for the treatment of mucocutaneous candidiasis. It has in vitro activity against yeasts and molds (such as Aspergillus spp and the Mucorales), but it has not been studied for the empiric treatment of invasive fungal infections in neutropenic patients or for the treatment of established mold infections. Furthermore, its availability only in an oral formulation and its variable absorption limit its use for treatment of suspected infection in most experts&rsquo; opinion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment and prevention of invasive aspergillosis\", section on 'Posaconazole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      A randomized trial compared IV followed by oral itraconazole to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate for up to 28 days as empiric therapy in 384 febrile neutropenic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/71\">",
"       71",
"      </a>",
"      ]. Itraconazole was at least as effective as amphotericin B (response rate 47 versus 38 percent), and significantly fewer patients had drug-related adverse effects (5 versus 54 percent). The median duration of neutropenia in this study was 10 and 8 days for the itraconazole and amphotericin groups, respectively. Five breakthrough fungal infections were observed in each group.",
"      <br/>",
"      <br/>",
"      Despite its efficacy, we do not recommend itraconazole for patients with neutropenic fever because it has several important drawbacks. It should not be used in patients with an estimated creatinine clearance below 30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and appropriate dosing in hepatic failure has not been well characterized. Itraconazole has negative inotropic properties and can induce or exacerbate congestive heart failure. The IV formulation of itraconazole is no longer available in the United States, and oral formulations have variable bioavailability. It also has a number of important drug interactions, most notably with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , and HMG-CoA reductase inhibitors (&ldquo;statins&rdquo;). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"       \"Pharmacology of azoles\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Fluconazole is generally not recommended for empiric antifungal therapy because of its lack of activity against molds, a major concern in patients with hematologic malignancies and those undergoing HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974423\">",
"    <span class=\"h3\">",
"     Preemptive antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to empiric antifungal therapy is preemptive therapy; this involves serial screening of high-risk patients for markers of fungal colonization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection in an attempt to prevent invasive infection. Such markers include laboratory tests (eg, Aspergillus galactomannan antigen, beta-D-glucan assay) and imaging tests (high-resolution chest computed tomography). If one of these markers suggests a fungal infection, antifungal therapy is started. This approach is best suited for patients receiving prophylaxis with an anti-yeast agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , where the concern is mainly mold pathogens and one is considering broadening the coverage to include an anti-mold agent.",
"   </p>",
"   <p>",
"    Some studies support the use of preemptive antifungal therapy. However, further study is necessary to establish the efficacy and safety of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974430\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an infectious source of fever is identified, antibiotics should be continued for at least the standard duration indicated for the specific infection (eg, 14 days for Escherichia coli bacteremia); antibiotics should also continue at least until the absolute neutrophil count (ANC) is &ge;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or longer if clinically indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When no source is identified and cultures are negative, the timing of discontinuation of antibiotics is usually dependent on resolution of fever and clear evidence of bone marrow recovery. If the patient has been afebrile for at least two days and the ANC is &gt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is showing a consistent increasing trend, antibiotics may be stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. An alternative approach in patients who remain neutropenic involves continuing antibiotics until an appropriate treatment course has been completed and all signs and symptoms of infection have resolved, and then switching to oral fluoroquinolone prophylaxis until marrow recovery has occurred; however, this approach has not been well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with an identifiable cause of fever (eg, a urinary tract infection caused by E. coli) who have had steady clinical improvement but who require continued antibiotic therapy following the resolution of neutropenia to complete the course of therapy, a switch from IV antibiotic therapy to appropriate oral agents can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974437\">",
"    <span class=\"h1\">",
"     CATHETER REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheter (CVC)-related infections are common in patients with neutropenic fever. If blood cultures drawn from the CVC become positive at least 120 minutes before peripheral blood cultures drawn at the same time, then the CVC is likely to be the source of the bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to antibiotics, CVC removal is recommended for patients with catheter-related bloodstream infections in which any of the following organisms is implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S. aureus",
"     </li>",
"     <li>",
"      P. aeruginosa",
"     </li>",
"     <li>",
"      Candida species (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H28#H28\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Catheter removal'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other fungi",
"     </li>",
"     <li>",
"      Rapidly growing nontuberculous mycobacteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This recommendation is based upon observational studies showing improved clearance of infection, and, in some cases, a mortality benefit, among patients with S. aureus, P. aeruginosa, or Candida spp bloodstream infections in whom the CVC was removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/72-77\">",
"     72-77",
"    </a>",
"    ]. In a study of cancer patients with bacteremia caused by rapidly growing mycobacteria, CVC removal was associated with a significantly reduced rate of relapse of bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/78\">",
"     78",
"    </a>",
"    ]. There are no studies that have demonstrated the benefit of CVC removal in patients with CVC-related bloodstream infections caused by fungi other than Candida spp, but CVC removal is generally recommended in such patients based upon the severity of these infections and the biologic plausibility of the potential benefit of this intervention.",
"   </p>",
"   <p>",
"    Antibiotics should be administered for a minimum of 14 days following catheter removal",
"    <strong>",
"     and",
"    </strong>",
"    clearance of blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter removal is also recommended for tunnel infection, port pocket infection, septic thrombosis, endocarditis, sepsis with hemodynamic instability, and bloodstream infection that persists despite &ge;72 hours of therapy with appropriate antibiotics, even when pathogens other than those described above are isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prolonged duration of treatment of four to six weeks is recommended for patients with complicated CVC-associated infections, such as those with deep tissue infection, endocarditis, septic thrombosis, or persistent bacteremia or fungemia occurring &gt;72 hours following catheter removal in a patient receiving appropriate antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence to support the need for an extended duration of therapy is strongest for S. aureus, but this approach is also suggested for complicated infections caused by other pathogens.",
"   </p>",
"   <p>",
"    For CVC-associated bacteremia caused by coagulase-negative staphylococci, the CVC may be retained; in this setting, patients are treated with systemic antibiotics with or without antibiotic lock therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Antibiotic lock therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=see_link&amp;anchor=H22#H22\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Antibiotic lock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the Infectious Diseases Society of America (IDSA) guidelines recommend CVC removal in patients with candidemia, some authors have suggested that catheter removal may not be necessary in neutropenic patients with candidemia, in whom the source is often the gastrointestinal tract, rather than the CVC. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Catheter removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120311467\">",
"    <span class=\"h1\">",
"     COLONY STIMULATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colony stimulating factors (CSFs; also known as myeloid growth factors or hematopoietic growth factors), such as granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF), are generally",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the management of patients with established fever and neutropenia, with some exceptions. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H1163951#H1163951\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Neutropenic fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974452\">",
"    <span class=\"h1\">",
"     MYELOID RECONSTITUTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be aware of the myeloid reconstitution syndrome, a circumstance in which there may be onset or progression of an inflammatory focus defined clinically or radiologically that manifests at the time of neutrophil recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/79\">",
"     79",
"    </a>",
"    ]. Because such processes may appear in the context of a persistent neutropenic fever syndrome, the likelihood of superinfection must be considered with respect to the antimicrobial spectrum of the patient&rsquo;s current empiric antibacterial therapy and the microbiologic differential diagnosis applicable to those circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link&amp;anchor=H247552339#H247552339\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenic fever syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974483\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the treatment of patients with neutropenic fever syndromes has improved greatly as demonstrated by a progressive decline in mortality rates since the prompt initiation of empiric coverage was implemented in the 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/20,80,81\">",
"     20,80,81",
"    </a>",
"    ]. Studies from the 1960s, before the routine use of empiric therapy, documented mortality rates of 90 percent in neutropenic patients with bacteremia caused by gram-negative bacilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Sepsis due to P. aeruginosa or Escherichia coli resulted in death within 48 hours after the first blood culture had been drawn in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a study of 41,779 adults with cancer who were hospitalized with neutropenic fever in the United States between 1995 and 2000, the in-hospital mortality was 9.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/86\">",
"     86",
"    </a>",
"    ]. The mortality rate depended upon the underlying malignancy: 8 percent in patients with solid tumors, 8.9 percent in patients with lymphoma, and 14.3 percent in patients with leukemia. The number of major comorbid conditions also significantly affected the mortality rate. Patients without any comorbidities had a 2.6 percent risk of dying, compared with 10.3 percent for patients with one comorbidity, 21.4 percent for patients with two comorbidities, 38.6 percent for patients with three comorbidities, and 50.6 percent for patients with four comorbidities.",
"   </p>",
"   <p>",
"    Outcomes are poor in neutropenic patients who are critically ill. In a cohort study conducted in 428 neutropenic patients with severe sepsis or septic shock in France between 1998 and 2008, the hospital mortality was 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/52/40778/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that influence the risk of treatment failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=see_link&amp;anchor=H608696459#H608696459\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\", section on 'Risk of treatment failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974590\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prophylaxis of infection in patients at risk for neutropenic fever is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974597\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974605\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria or fungi that translocate across intestinal mucosal surfaces. Because neutropenic patients are unable to mount robust inflammatory responses, serious infection can occur with minimal symptoms and signs. In such patients, fever is often the only sign of infection. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death. (See",
"      <a class=\"local\" href=\"#H154973506\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is crucial to assess the risk of serious complications in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization. High-risk neutropenic patients are those with an absolute neutrophil count (ANC) &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days or evidence of ongoing comorbid conditions (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"mobipreview.htm?39/26/40364\">",
"       table 1",
"      </a>",
"      ). Profound prolonged neutropenia is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia. (See",
"      <a class=\"local\" href=\"#H154973748\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974613\">",
"    <span class=\"h2\">",
"     Initial empiric therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever in high-risk neutropenic patients should be considered a medical emergency. Empiric broad-spectrum antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed (",
"      <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"mobipreview.htm?40/56/41856\">",
"       algorithm 1",
"      </a>",
"      ). Antibiotics should be administered within",
"      <strong>",
"       60 minutes",
"      </strong>",
"      of presentation in patients presenting with neutropenic fever. (See",
"      <a class=\"local\" href=\"#H154974106\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H468185456\">",
"       'Timing of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial antibiotic selection should be guided by the patient's history, allergies, symptoms, signs, recent antibiotic use and culture data, and awareness of institutional nosocomial infection and susceptibility patterns. Ideally, antibiotics should be bactericidal. (See",
"      <a class=\"local\" href=\"#H154974106\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For high-risk patients with neutropenic fever, we recommend empiric monotherapy with an anti-pseudomonal beta-lactam agent, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      , imipenem, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"mobipreview.htm?40/56/41856\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Because of high rates of resistance,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      is no longer recommended at most centers, but it is reasonable to use it at centers with low rates of resistance. (See",
"      <a class=\"local\" href=\"#H154974278\">",
"       'Initial regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (or another agent that targets gram-positive cocci) as a standard part of the initial regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In contrast, gram-positive coverage should be added in patients with suspected central venous catheter-related infection, skin or soft tissue infection, pneumonia, or hemodynamic instability. For patients with complicated presentations (eg, hypotension; central venous catheter, skin, or soft tissue infections; pneumonia), coverage should be broadened to cover the likely pathogens (eg, resistant gram-negative, gram-positive, and anaerobic bacteria, as well as fungi). (See",
"      <a class=\"local\" href=\"#H154974278\">",
"       'Initial regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H154974343\">",
"       'Antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974621\">",
"    <span class=\"h2\">",
"     Empiric therapy for persistent fever",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent fever alone in an otherwise stable patient is",
"      <strong>",
"       not",
"      </strong>",
"      sufficient justification for modification of the initial antibiotic regimen. However, modifications to the initial regimen should be considered for patients at risk for infection with antibiotic-resistant organisms, for patients who are clinically unstable, and for patients who have positive blood cultures that are suggestive of a resistant infection. (See",
"      <a class=\"local\" href=\"#H154974321\">",
"       'Modifications to the regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H423440041\">",
"       'Persistent fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who remain febrile after the initiation of empiric antibiotics should be reevaluated for possible infectious sources. Management algorithms have been developed for the reassessment of neutropenic patients with persistent fever (",
"      <a class=\"graphic graphic_algorithm graphicRef74452 \" href=\"mobipreview.htm?0/14/225\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"mobipreview.htm?11/47/12017\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H154974321\">",
"       'Modifications to the regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the empiric addition of an antifungal agent for neutropenic patients who are persistently febrile after four to seven days despite broad-spectrum antibacterials and who have no documented source of infection (",
"      <a class=\"graphic graphic_algorithm graphicRef53163 \" href=\"mobipreview.htm?11/47/12017\">",
"       algorithm 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H154974358\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of antifungal agent for empiric therapy depends upon which fungi are most likely to be causing infection, as well as toxicity profiles and cost:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For persistently febrile patients who have not been receiving antifungal prophylaxis and who have no obvious site of infection, such as pulmonary nodules, we favor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      (or another echinocandin) since Candida spp is the most likely cause in such patients.",
"     </li>",
"     <li>",
"      For persistently febrile patients with pulmonary nodules or nodular pulmonary infiltrates, invasive mold infection should be strongly suspected. In such patients, we favor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      or a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For persistently febrile patients who have been receiving anti-mold prophylaxis, a different class of antifungal agent with activity against molds should be used for empiric therapy. (See",
"      <a class=\"local\" href=\"#H154974365\">",
"       'Choice of drug'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974629\">",
"    <span class=\"h2\">",
"     Catheter removal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to antimicrobial therapy, we recommend central venous catheter removal for patients with catheter-related bloodstream infections caused by S. aureus, P. aeruginosa, Candida spp, or rapidly growing nontuberculous mycobacteria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also recommend central venous catheter removal for patients with cathether-related bloodstream infections with fungi other than Candida spp (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The central venous catheter should also be removed in patients with complicated infections (eg, tunnel infection, port pocket infection). (See",
"      <a class=\"local\" href=\"#H154974437\">",
"       'Catheter removal'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Removal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H28#H28\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Catheter removal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154974637\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Gregory K Robbins, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/1\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/3\">",
"      Link H, B&ouml;hme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 Suppl 2:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/4\">",
"      Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin Cheng, et al. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 2005; 38:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/5\">",
"      Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004; 39 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/7\">",
"      Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/8\">",
"      McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Northern Ireland Cancer Network, Belfast 2010. p. 1-11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/10\">",
"      Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/11\">",
"      Sickles EA, Young VM, Greene WH, Wiernik PH. Pneumonia in acute leukemia. Ann Intern Med 1973; 79:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/12\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/13\">",
"      American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/14\">",
"      Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/15\">",
"      Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/16\">",
"      Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis 2005; 40 Suppl 4:S253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/17\">",
"      Lazarus HM, Creger RJ, Gerson SL. Infectious emergencies in oncology patients. Semin Oncol 1989; 16:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/18\">",
"      Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005; 40 Suppl 4:S246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/19\">",
"      Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998; 102:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/20\">",
"      Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 Suppl 4:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/21\">",
"      Coullioud D, Van der Auwera P, Viot M, Lasset C. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer). Support Care Cancer 1993; 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/22\">",
"      Mathur P, Chaudhry R, Kumar L, et al. A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes. Med Oncol 2002; 19:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/23\">",
"      Brown EA, Talbot GH, Provencher M, Cassileth P. Anaerobic bacteremia in patients with acute leukemia. Infect Control Hosp Epidemiol 1989; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/24\">",
"      Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/25\">",
"      Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/26\">",
"      Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/27\">",
"      Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003; :CD003038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/28\">",
"      Feld R, DePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18:3690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/29\">",
"      Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/30\">",
"      Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/31\">",
"      Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/32\">",
"      Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/33\">",
"      Freifeld AG, Sepkowitz K. Cefepime and death: reality to the rescue. Clin Infect Dis 2010; 51:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/34\">",
"      Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/35\">",
"      Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002; 137:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/36\">",
"      Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2005; 80:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/37\">",
"      Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/38\">",
"      Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/39\">",
"      Paul M, Borok S, Fraser A, et al. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 2005; :CD003914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/40\">",
"      Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/41\">",
"      Aoun M. Review: additional anti-gram-positive antibiotics do not reduce all-cause mortality in cancer and febrile neutropenia. ACP J Club 2006; 144:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/42\">",
"      Dompeling EC, Donnelly JP, Deresinski SC, et al. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/43\">",
"      Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988; 319:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/44\">",
"      Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/45\">",
"      Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 2004; 39:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/46\">",
"      Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 1986; 81:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/47\">",
"      Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003; 37:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/48\">",
"      Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/49\">",
"      Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/50\">",
"      Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol 2012; 19:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/51\">",
"      Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/52\">",
"      Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005; 103:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/53\">",
"      Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/54\">",
"      Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/55\">",
"      Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/56\">",
"      Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: current status. Curr Top Med Mycol 1997; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/57\">",
"      Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Williston Park) 2001; 15:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/58\">",
"      Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol 1979; 72:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/59\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/60\">",
"      Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/61\">",
"      Klastersky J. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical? N Engl J Med 2004; 351:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/62\">",
"      Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/63\">",
"      Powers JH. Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of P values. Clin Infect Dis 2004; 39:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/64\">",
"      Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/65\">",
"      Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/66\">",
"      Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2007; 46:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/67\">",
"      Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006; 45:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/68\">",
"      Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/69\">",
"      Marr KA. Empirical antifungal therapy--new options, new tradeoffs. N Engl J Med 2002; 346:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/70\">",
"      Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/71\">",
"      Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/72\">",
"      Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/73\">",
"      Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/74\">",
"      Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004; 25:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/75\">",
"      Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/76\">",
"      Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004; 38:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/77\">",
"      Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/78\">",
"      El Helou G, Hachem R, Viola GM, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients. Clin Infect Dis 2013; 56:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/79\">",
"      Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/80\">",
"      Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/81\">",
"      Klastersky J, Cappel R, Debusscher L. Evaluation of gentamicin with carbenicillin in infections due to gram-negative bacilli. Curr Ther Res Clin Exp 1971; 13:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/82\">",
"      Klastersky J. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy? J Antimicrob Chemother 2009; 63 Suppl 1:i14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/83\">",
"      Gram-negative bacteremia, clinical, laboratory and therapeutic observations. Arch Intern Med 1962; 110:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/84\">",
"      Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/85\">",
"      Bodey GP, Elting L, Kassamali H, Lim BP. Escherichia coli bacteremia in cancer patients. Am J Med 1986; 81:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/52/40778/abstract/86\">",
"      Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1400 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40778=[""].join("\n");
var outline_f39_52_40778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H154974597\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154973506\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154973513\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154973521\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154973529\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154973595\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154973748\">",
"      RISK OF SERIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154973860\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154973874\">",
"      Risk of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154973912\">",
"      Risk of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154973949\">",
"      Identification of SIRS and sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974079\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974086\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974106\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H468185456\">",
"      - Timing of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974271\">",
"      - Spectrum of coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974278\">",
"      Initial regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974285\">",
"      - Comparisons of regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974293\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974300\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974307\">",
"      - Penicillin-allergic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974314\">",
"      Addition of gram-positive coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974321\">",
"      Modifications to the regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H423440041\">",
"      - Persistent fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974343\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974350\">",
"      Addition of an antifungal agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974358\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974365\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974372\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974379\">",
"      - Studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974386\">",
"      Amphotericin B formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974401\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974408\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H154974415\">",
"      Other azoles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154974423\">",
"      - Preemptive antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974430\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974437\">",
"      CATHETER REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H120311467\">",
"      COLONY STIMULATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974452\">",
"      MYELOID RECONSTITUTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974483\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974590\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974597\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974605\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974613\">",
"      Initial empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974621\">",
"      Empiric therapy for persistent fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154974629\">",
"      Catheter removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154974637\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1400|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/56/41856\" title=\"algorithm 1\">",
"      Neutropenic fever initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/14/225\" title=\"algorithm 2\">",
"      Neutropenic fever reassessment after 2 to 4 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/47/12017\" title=\"algorithm 3\">",
"      Fever neutropenia reassessment after four days",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/26/40364\" title=\"table 1\">",
"      High-risk patients with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/55/24444\" title=\"table 2\">",
"      Diagnostic evaluation fever and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/44/718\" title=\"table 3\">",
"      Pathogens in neutropenic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/34/14881?source=related_link\" title=\"calculator 2\">",
"      Calculator: Multinational Association for Supportive Care in Cancer (MASCC) risk index for patients with neutropenic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20681?source=related_link\">",
"      Gram-negative bacillary bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1785?source=related_link\">",
"      Infections due to Trichosporon species and Blastoschizomyces capitatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9338?source=related_link\">",
"      Pharmacology of echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27125?source=related_link\">",
"      Typhlitis (neutropenic enterocolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_52_40779="Criteria for MMS";
var content_f39_52_40779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for performing Mohs micrographic surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumor characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large tumor (&gt;2 cm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly defined clinical borders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incompletely excised (positive margins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Aggressive histologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Morpheaform, micronodular, infiltrative BCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Basosquamous features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Poorly differentiated and deeply infiltrative SCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perineural invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic scar (Marjolin's ulcer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppressed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irradiated skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic syndrome (eg, xeroderma pigmentosum, Gorlin or nevoid BCC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anatomic location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Areas where tissue preservation is essential (including eyes, nose, hands/feet and genitalia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embryonic fusion lines (preauricular, nasolabial fold, inner canthus and philtrum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Mask areas\" of face (central face, periorbital, nose, lips)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40779=[""].join("\n");
var outline_f39_52_40779=null;
var title_f39_52_40780="Indications for ICD in patients with unexplained syncope";
var content_f39_52_40780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for ICD in patients with unexplained syncope and high risk of SCD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical situation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with ischaemic cardiomyopathy with severely depressed LVEF or HF, ICD therapy is indicated according to current guidelines for ICD&mdash;cardiac resynchronization therapy implantation",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with non-ischaemic cardiomyopathy with severely depressed LVEF or HF, ICD therapy is indicated according to current guidelines for ICD&mdash;cardiac resynchronization therapy implantation",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In hypertrophic cardiomyopathy ICD therapy should be considered in patients at high risk (see text)",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        In non-high risk, consider ILR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In right ventricular cardiomyopathy ICD therapy should be considered in patients at high risk (see text)",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        In non-high risk, consider ILR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In Brugada syndrome ICD therapy should be considered in patients with spontaneous type I ECG",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        In the absence of spontaneous type I pattern, consider ILR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In long QT syndrome, ICD therapy, in conjunction with &beta;-blockers, should be considered in patients at risk",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        In non-high risk, consider ILR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with ischaemic cardiomyopathy without severely depressed LVEF or HF and negative programmed electrical stimulation ICD therapy may be considered",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Consider ILR to help define the nature of unexplained syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with non-ischaemic cardiomyopathy without severely depressed LVEF or HF ICD therapy may be considered",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Consider ILR to help define the nature of unexplained syncope",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; ECG: electrocardiogram; ICD: implantable cardioverter defibrillator; ILR: implantable loop recorder; LVEF: left ventricular ejection fraction; SCD: sudden cardiac death.",
"     <br>",
"      * Class of recommendation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Level of evidence.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40780=[""].join("\n");
var outline_f39_52_40780=null;
var title_f39_52_40781="Gemfibrozil events low HDL";
var content_f39_52_40781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gemfibrozil reduces cardiac death and nonfatal myocardial infarction in patients with low HDL cholesterol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The VA-HIT trial of 2531 patients with coronary heart disease and low LDL and HDL cholesterol showed that the incidence of cardiac death and nonfatal myocardial infarction was lower with gemfibrozil (17.3 versus 21.7 percent for placebo, relative risk reduction 22 percent, p = 0.006).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rubins, HB, Robins, SJ, Collins, D, et al, for the Veterans Affairs High Density Lipoprotein Cholesterol Interventions Trial Study Group, N Engl J Med 1999; 341: 410.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40781=[""].join("\n");
var outline_f39_52_40781=null;
var title_f39_52_40782="Schematic of echo findings in PH";
var content_f39_52_40782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Representation of echocardiographic findings in severe pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 337px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of two-dimensional and Doppler echocardiographic changes in severe pulmonary hypertension. The main findings are right ventricular enlargement (RVE), right ventricular hypertrophy (RVH), right atrial enlargement (RAE), functional tricuspid regurgitation (TR) with a high velocity regurgitant jet by Doppler (TR jet), and a mid-systolic notch on the pulmonary artery Doppler flow tracing (PA flow). The interventricular septum is shifted toward the left ventricular cavity, resulting in flattening of the ventricular septum particularly during systole; this flattening is most evident in the short-axis left ventricular cavity view (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Otto C. Cardiomyopathies, hypertensive and pulmonary heart disease. In: Textbook of Clinical Echocardiography, Otto C, Pearlman AS (Eds), Saunders, Philadelphia, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40782=[""].join("\n");
var outline_f39_52_40782=null;
var title_f39_52_40783="King LT anatomy";
var content_f39_52_40783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    King LT placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King Systems Corporation. Copyright &copy; 2008 King Systems Corporation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_52_40783=[""].join("\n");
var outline_f39_52_40783=null;
